Document:

EX-10.4

 Exhibit 10.4 

OMNIBUS AMENDMENT 
 This OMNIBUS AMENDMENT
(this “Agreement”) dated as of January 15, 2021 is among Penn Virginia Holdings, LLC (as successor to Penn Virginia Holding Corp.), a Delaware limited liability company (the “Borrower”), Penn Virginia
Corporation, a Virginia corporation (“Holdings”), the guarantors listed on the signature page hereto (the “Guarantors”), the Consenting Lenders (as defined below) party hereto and Ares Capital Corporation, as
administrative agent and collateral agent for the Lenders (in such capacities, the “Agent”). 
 RECITALS 

 

	 	A.	 The Borrower, Holdings, Jefferies Finance LLC, as administrative agent and collateral agent (in such
capacities, the “Existing Agent”) for the Lenders, and the financial institutions party thereto from time to time, as lenders (the “Lenders”) are parties to that certain Credit Agreement dated as of
September 29, 2017 (amended, restated, supplemented or otherwise modified from time to time prior to the date hereof, the “Credit Agreement”). 

 

	 	B.	 On the date hereof, the Borrower, Holdings, the Guarantors party thereto, the Lenders party thereto, the
Existing Agent and Ares Capital Corporation entered into that certain Successor Agent, Consent and Amendment Agreement (the “Successor Agent Agreement”) pursuant to which, among other things, (i) the Existing Agent resigned as
administrative agent and collateral agent under the Credit Agreement and the other Loan Documents, (ii) the Lenders party to the Successor Agent Agreement appointed Ares Capital Corporation as successor Administrative Agent and Collateral Agent
(in such capacities, the “Successor Agent”) and (iii) Ares Capital Corporation accepted its appointment as Successor Agent, subject to the terms and conditions set forth therein. 

 

	 	C.	 The Borrower, Holdings, each of the Guarantors party thereto and the Lenders party thereto entered into that
certain Amendment No. 1 to Credit Agreement, dated as of November 2, 2020 (“Amendment No. 1”) pursuant to which the parties thereto agreed to, among other things, amend the Credit Agreement in its
entirety to read as set forth in Annex A thereto (such Annex A, the “Proposed Amended Credit Agreement”), to be effective on the “Effective Date” as defined therein (the “Amendment No. 1
Effective Date”) 

  

	 	D.	 The Borrower, Holdings, each of the Guarantors, the Agent and the Lenders party hereto (each such Lender, a
“Consenting Lender”) wish to, subject to the terms and conditions set forth herein, amend Amendment No. 1 by modifying the Proposed Amended Credit Agreement as provided herein. 

 

	 	E.	 In connection with the transactions contemplated by Amendment No. 1 and the Revolver Amendment (as defined
in the Proposed Amended Credit Agreement), the Consenting Lenders wish to, subject to the terms and conditions set forth herein, (i) authorize the Agent to enter into an amendment to the Intercreditor Agreement in substantially the form
attached hereto as Exhibit A (the “Intercreditor Agreement Amendment”) and (ii) direct the Agent to release Holdings from its guaranty obligations under the Loan Documents and to release the assets of Holdings from the Liens
created under the Loan Documents, in each case, upon the occurrence of the Amendment No. 1 Effective Date. 

 NOW THEREFORE, in consideration of the premises and the mutual covenants, representations
and warranties contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows: 

Section 1. Defined Terms. As used in this Agreement, each of the terms defined in the opening paragraph and the
Recitals above shall have the meanings assigned to such terms therein. Each term defined in the Credit Agreement and used herein without definition shall have the meaning assigned to such term in the Credit Agreement, unless expressly provided to
the contrary. 
 Section 2. Other Definitional Provisions. The definitions of terms herein shall apply equally to the singular
and plural forms of the terms defined. Whenever the context may require, any pronoun shall include the corresponding masculine, feminine and neuter forms. The words “include,” “includes” and “including” shall be deemed
to be followed by the phrase “without limitation.” The word “will” shall be construed to have the same meaning and effect as the word “shall.” Unless the context requires otherwise (a) any definition of or
reference to any agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such
amendments, supplements or modifications set forth herein), (b) any reference herein to any Person shall be construed to include such Person’s successors and assigns, (c) the words “herein,” “hereof” and
“hereunder,” and words of similar import, shall be construed to refer to this Agreement in its entirety and not to any particular provision hereof, (d) all references herein to Articles, Sections, Exhibits and Schedules shall be
construed to refer to Articles and Sections of, and Exhibits and Schedules to, this Agreement, (e) any reference to any law or regulation herein shall, unless otherwise specified, refer to such law or regulation as amended, modified or
supplemented from time to time, and (f) the words “asset” and “property” shall be construed to have the same meaning and effect and to refer to any and all tangible and intangible assets and properties, including cash,
securities, accounts and contract rights. Titles and captions of Articles, Sections and subsections in this Agreement are for convenience only, and neither limit nor amplify the provisions of this Agreement. 

Section 3. Amendments to Amendment No. 1. Effective as of the Omnibus Effective Date, Amendment
No. 1 shall be amended by amending the Proposed Amended Credit Agreement as follows: 
 (a)    Each instance of the
phrase “Penn Virginia Holding LLC” in the Proposed Amended Credit Agreement shall be replaced with the phrase “Penn Virginia Holdings, LLC”. 

(b)    Each instance of the phrase “Loan Party” shall be replaced with the phrase “Group Member” and
each instance of the phrase “Loan Parties” shall be replaced with the phrase “Group Members” in the following provisions of the Proposed Amended Credit Agreement: the definitions of “Employee Benefit Plan”, “ERISA
Affiliate”, “Indemnified Taxes”, “Termination Event” in Section 1.01, Section 2.08(c), the lead-in sentence to Article IV, Section 4.02, Section 4.03, Sections 4.06
through 4.14 (inclusive), Section 4.21, Section 4.25, Section 4.29, Section 5.01, 

  
 2 

 
Section 5.04, Section 5.05, Section 5.06(h) through (p) (inclusive), Section 5.06(t), Section 5.13, the lead-in sentence to
Article VI, Section 6.09, Section 6.13, Section 6.20, Section 7.01(b) through (g) (inclusive), Section 7.01(i), Section 7.05, Section 8.01, Section 8.03, Section 8.07, Section 8.10,
Section 9.02(d), Section 9.05(b), Section 9.06, Section 9.07(a), Section 9.09, Section 9.13, Section 9.16, Section 9.17, Section 9.19, Section 9.22, Section 9.25 and Section 9.26. 

(c)    The definition of “Excluded Subsidiary” in Section 1.01 of the Proposed Amended Credit Agreement is
hereby amended and restated in its entirety as follows: 
 “Excluded Subsidiary” means any Restricted Subsidiary that is
not required to become a Guarantor pursuant to Section 5.08(a) [Collateral Matters; Guaranties]. 

(d)    The definition of “General Partner” in Section 1.01 of the Proposed Amended Credit Agreement is
hereby amended and restated in its entirety as follows: 
 “General Partner” means PV Energy Holdings GP, LLC, a Delaware
limited liability company. 
 (e)    The definition of “Guarantor” in Section 1.01 of the Proposed
Amended Credit Agreement is hereby amended and restated in its entirety as follows: 
 “Guarantor” means
(a) Intermediate, (b) General Partner, (c) each other Restricted Subsidiary of Holdings (other than Excluded Subsidiaries), (d) each Restricted Subsidiary of Holdings that voluntarily executes a Guaranty and (e) to the extent required
by Section 5.11(d) [Further Assurances; Cure of Title Defects], Holdings; provided that, notwithstanding anything in the Loan Documents, Guarantor shall in no event include any Excluded Tax Subsidiary. 

(f)    Section 1.01 of the Proposed Amended Credit Agreement is hereby amended by adding the following defined terms in
the appropriate alphabetical order: 
 “Beneficial Ownership Certification” means a certification regarding beneficial
ownership as required by the Beneficial Ownership Regulation, which certification shall be substantially similar in form and substance to the form of Certification Regarding Beneficial Owners of Legal Entity Customers published jointly, in May 2018,
by the Loan Syndications and Trading Association and Securities Industry and Financial Markets Association. 
 “Beneficial Ownership
Regulation” means 31 C.F.R. § 1010.230. 
 “Group Member” means (a) Holdings and (b) the Loan
Parties. 
 (g)    Article I of the Proposed Amended Credit Agreement is hereby amended by adding a new
Section 1.10 that shall read in its entirety as follows: 
 Section 1.10. Divisions. For all purposes under
the Loan Documents, in connection with any division or plan of division under Delaware law (or any comparable event under a different jurisdiction’s Legal Requirements): (a) if any asset, Property,

  
 3 

 
right, obligation, or liability of any Person becomes the asset, Property, right, obligation, or liability of a different Person, then it shall be deemed to have been transferred from the
original Person to the subsequent Person, and (b) if any new Person comes into existence, such new Person shall be deemed to have been organized on the first date of its existence by the holders of its Equity Interests at such time. 

(h)    Section 4.04 of the Proposed Amended Credit Agreement is hereby amended and restated in its entirety as follows:

 Section 4.04. Enforceable Obligations. This Agreement, the Notes, and the other Loan Documents to which any
Group Member is a party have been duly executed and delivered by such Group Members. Each Loan Document is the legal, valid, and binding obligation of Holdings, the Borrower and each Guarantor which is a party to it enforceable against Holdings, the
Borrower and each such Guarantor in accordance with its terms, except as such enforceability may be limited by any applicable Debtor Relief Laws. 

(i)    Section 4.06 of the Proposed Amended Credit Agreement is hereby amended by adding the following sentence at the end
of such Section: 
 The information included in any Beneficial Ownership Certification provided to any Lender in connection with this
Agreement is true and correct in all respects as of the date delivered. 
 (j)    Section 5.06(q) of the Proposed
Amended Credit Agreement is hereby amended and restated in its entirety as follows: 
 (q) USA Patriot Act; Beneficial Ownership.
Promptly, following a request by any Lender, all documentation and other information (including, without limitation, a Beneficial Ownership Certification) that such Lender reasonably requests in order to comply with its ongoing obligations under
applicable “know your customer” and anti-money laundering rules and regulations, including the Patriot Act, and the Beneficial Ownership Regulation; 

(k)    Section 5.06 of the Proposed Amended Credit Agreement is hereby amended by deleting the word “and” at the
end of clause (s), replacing the “.” at the end of clause (t) with “; and” and adding a new clause (u) that shall read in its entirety as follows: 

(u) Beneficial Ownership. Prompt written notice of any change in the information provided in any Beneficial Ownership Certification
delivered to a Lender that would result in a change to the list of beneficial owners identified in such Beneficial Ownership Certification. 

  
 4 

 (l)    The last sentence of Section 5.11(a) of the Proposed Amended
Credit Agreement is hereby amended and restated in its entirety as follows: 
 Each of Holdings and the Borrower, at its expense will, and
will cause each of their respective Restricted Subsidiaries to, promptly execute and deliver to the Administrative Agent upon its reasonable request all such other documents, agreements and instruments to comply with or accomplish the covenants and
agreements of Holdings and the Loan Parties, as the case may be, in the Security Instruments and this Agreement, or to further evidence and more fully describe the collateral intended as security for the Obligations, or to correct any omissions in
the Security Instruments, or to state more fully the security obligations set out herein or in any of the Security Instruments, or to perfect, protect or preserve any Liens created pursuant to any of the Security Instruments, or to make any
recordings, to file any notices or obtain any consents, all as may be necessary or appropriate in connection therewith or to enable the Administrative Agent to exercise and enforce its rights and remedies with respect to any Collateral. 

(m)    Section 5.11(c) of the Proposed Amended Credit Agreement is hereby amended and restated in its entirety as follows:

 (c) Holdings (i) shall cause 100% of the Equity Interests in the Borrower to at all times constitute Collateral and be subject to an
Acceptable Security Interest in favor of the Secured Parties and shall cause each Subsidiary directly owning such Equity Interests to be a Guarantor and (ii) shall not create, assume, incur or suffer to exist, any Lien on any Equity Interests
of Intermediate or the General Partner held by Holdings other than (A) those permitted under Section 6.01(c) [Liens, Etc.] and (B) Liens granted under the Security Instruments and Liens granted under the
corresponding provisions of the First Lien Loan Documents. 
 (n)    Section 5.11(d) of the Proposed Amended Credit
Agreement is hereby amended and restated in its entirety as follows: 
 (d) Promptly after any breach by Holdings of the covenant in
Section 6.19 [Passive Holding Company], then Holdings shall become a Guarantor by delivering a Guaranty or a supplement to an existing Guaranty executed and delivered by Holdings in form and substance reasonably
satisfactory to the Administrative Agent, (ii) execute and deliver a Security Agreement or a supplement to an existing Security Agreement and such other Security Instruments executed and delivered by Holdings as the Administrative Agent may
reasonably request in order to grant to the Administrative Agent an Acceptable Security Interest in the assets of Holdings then owned or thereafter acquired, and (iii) deliver to the Administrative Agent certificates, opinions of counsel, title
opinions or other documents as the Administrative Agent may reasonably request, including all documentation and other information that any Lender may reasonably request in order to comply with its ongoing obligations under applicable “know your
customer” and anti-money laundering rules and regulations, including the Patriot Act. 

  
 5 

 (o)    Section 6.01(j) of the Proposed Amended Credit Agreement is
hereby amended and restated in its entirety as follows: 
 (j) (i) Liens of a collecting bank arising in the ordinary course of
business under Section 4- 210 of the Uniform Commercial Code in effect in the relevant jurisdiction and (ii) Liens of any depositary bank in connection with statutory, common law and contractual
rights of set-off and recoupment with respect to any Deposit Account of Holdings, Intermediate, General Partner, the Borrower or any Restricted Subsidiary thereof; 

(p)    Section 6.01(o) of the Proposed Amended Credit Agreement is hereby amended and restated in its entirety as follows:

 (o) Liens on cash or cash equivalents in favor of any commercial bank to secure any and all obligations of Holdings and any Loan Party,
whether absolute or contingent and howsoever and whensoever created, arising, evidenced or acquired (including all renewals, extensions and modifications thereof and substitutions therefor) in connection with (i) commercial credit cards,
(ii) stored value cards and (iii) any other Treasury Management Arrangement (including, without limitation, controlled disbursement, purchase card arrangements, automated clearinghouse transactions, return items, overdrafts and interstate
depository network services); 
 (q)    Section 6.04(b) of the Proposed Amended Credit Agreement is hereby amended and
restated in its entirety as follows: 
 (b) merge or consolidate with or into any other Person; provided that (i) the Borrower
may merge with or may be consolidated into any Parent Entity or Subsidiary Guarantor if the Borrower is the surviving entity, (ii) any Subsidiary Guarantor may merge with or may be consolidated into any other Subsidiary Guarantor,
(iii) any Restricted Subsidiary of the Borrower that is not a Guarantor may merge with or may be consolidated into the Borrower or any other Restricted Subsidiary of the Borrower, (iv) any Restricted Subsidiary of the Borrower may merge or
may be consolidated with any other Person as part of a Disposition permitted by Section 6.04(c) [Merger or Consolidation; Asset Sales] and (v) any Parent Entity may merge with or may be consolidated into any Parent
Entity or any Subsidiary Guarantor if a Loan Party is the surviving entity; or 
 (r)    Section 6.04(c)(iii) of the
Proposed Amended Credit Agreement is hereby amended and restated in its entirety as follows: 
 (iii) the Disposition of Property to a Loan
Party, between or among Loan Parties or between or among Restricted Subsidiaries that are not Loan Parties; 

(s)    Section 6.05(d) of the Proposed Amended Credit Agreement is hereby amended and restated in its entirety as follows:

 (d) repurchases of Equity Interests in Holdings or any Loan Party deemed to occur upon exercise of stock options or warrants or similar
rights if such Equity Interests represents a portion of the exercise price of such options or warrants or similar rights shall be permitted (as long as Holdings or the Loan Parties make no payment in connection therewith that is not otherwise
permitted hereunder); 

  
 6 

 (t)    Section 6.05(e) of the Proposed Amended Credit Agreement is
hereby amended and restated in its entirety as follows: 
 (e) any purchase, repurchase, redemption, defeasance or other acquisition or
retirement of Equity Interests made by exchange (including any such exchange pursuant to the exercise of a conversion right or privilege in connection with which cash is paid in lieu of the issuance of fractional shares) for, or out of the proceeds
of the substantially concurrent sale of, Equity Interests of any Parent Entity or a substantially concurrent contribution to the equity of any Parent Entity, in each case, occurring after the date of this Agreement; 

(u)    Section 6.05 of the Proposed Amended Credit Agreement is hereby amended by deleting the “and” at the end
of clause (f), replacing the “.” at the end of clause (g) with “; and” and adding a new clause (h) that shall read in its entirety as follows: 

(h) Restricted Payments among Parent Entities. 

(v)    Section 6.19 of the Proposed Amended Credit Agreement is hereby amended and restated in its entirety as follows:

  

	 	(a)	 Notwithstanding anything herein to the contrary, Holdings shall not: 

 

	 	(i)	 hold any assets other than (A) the Equity Interests of General Partner and Intermediate,
(B) agreements relating to the issuance, sale, purchase, repurchase or registration of securities of Holdings, (C) minute books and other corporate books and records of Holdings and (D) other miscellaneous non-material assets incidental to the ownership of the Equity Interests of General Partner and Intermediate or to the maintenance of the Borrower’s or Holdings’ corporate existence; 

 

	 	(ii)	 have any Indebtedness, obligations or other liabilities other than (A) its liabilities under the Loan
Documents and liabilities under the First Lien Loan Documents, (B) Tax liabilities arising in the ordinary course of business, (C) corporate, administrative and operating expenses in the ordinary course of business, (D) liabilities
(but not Indebtedness) under any contracts or agreements described in clause (a)(i)(B) of this Section and (E) Indebtedness (but not Indebtedness for borrowed money) incurred in the ordinary course of business and permitted under
Section 6.02 which are incidental to the operating and maintenance of Holdings’, the Borrower’s and their respective Subsidiaries’ business; or 

 

	 	(iii)	 engage in any activities or business other than (i) issuing shares of its own Equity Interests (other than
Disqualified Equity Interests) the net proceeds of which are distributed to Intermediate, (ii) holding the assets and incurring the liabilities described in this Section 6.19(a) [Passive Holding Company] and activities

  
 7 

	 	
incidental and related thereto, (iii) making payments, dividends, distributions, issuances or other activities permitted pursuant to Section 6.05 [Restricted
Payments]. 

 (b)    Notwithstanding anything herein to the contrary, Holdings shall not
permit the General Partner to, and the General Partner agrees not to: 
  

	 	(i)	 hold any assets other than (A) the Equity Interests of Intermediate, (B) agreements relating to the
issuance, sale, purchase, repurchase or registration of securities of General Partner, (C) minute books and other corporate books and records of General Partner and (D) other miscellaneous
non-material assets incidental to the ownership of the Equity Interests of Intermediate or to the maintenance of the General Partner’s legal existence; 

 

	 	(ii)	 have any Indebtedness, obligations or other liabilities other than (A) the liabilities under the Loan
Documents and liabilities under the First Lien Loan Documents, (B) Tax liabilities arising in the ordinary course of business, (C) corporate, administrative and operating expenses in the ordinary course of business, (D) liabilities
(but not Indebtedness) under any contracts or agreements described in clause (b)(i)(B) of this Section and (E) Indebtedness (but not Indebtedness for borrowed money) incurred in the ordinary course of business and permitted under
Section 6.02 which are incidental to the operating and maintenance of Holdings’, the Borrower’s and their respective Subsidiaries’ business; or 

 

	 	(iii)	 engage in any activities or business other than (A) issuing shares of its own Equity Interests (other than
Disqualified Equity Interests), (B) holding the assets and incurring the liabilities described in this Section 6.19(b) [Passive Holding Company] and activities incidental and related thereto or (C) making payments,
dividends, distributions, issuances or other activities permitted pursuant to Section 6.05 [Restricted Payments]; provided, however, that General Partner shall be permitted to engage in the RCR Transactions.

 (c)    Notwithstanding anything herein to the contrary, Holdings shall not permit
Intermediate to, and Intermediate agrees not to: 
  

	 	(i)	 hold any assets other than (A) the Equity Interests of Borrower, (B) agreements relating to the
issuance, sale, purchase, repurchase or registration of securities of Intermediate, (C) minute books and other corporate books and records of Intermediate and (D) other miscellaneous non-material
assets incidental to the ownership of the Equity Interests of Borrower or to the maintenance of Intermediate’s legal existence; 

  
 8 

	 	(ii)	 have any Indebtedness, obligations or other liabilities other than (A) the liabilities under the Loan
Documents and liabilities under the First Lien Loan Documents, (B) Tax liabilities arising in the ordinary course of business, (C) corporate, administrative and operating expenses in the ordinary course of business, (D) liabilities
(but not Indebtedness) under any contracts or agreements described in (c)(i)(B) of this Section and (E) Indebtedness (but not Indebtedness for borrowed money) incurred in the ordinary course of business and permitted under Section 6.02
which are incidental to the operating and maintenance of Holdings’, the Borrower’s and their respective Subsidiaries’ business ; or 

  

	 	(iii)	 engage in any activities or business other than (A) issuing shares of its own Equity Interests (other than
Disqualified Equity Interests), (B) holding the assets and incurring the liabilities described in this Section 6.19(c) [Passive Holding Company] and activities incidental and related thereto or (C) making payments,
dividends, distributions, issuances or other activities permitted pursuant to Section 6.05 [Restricted Payments]; provided, however, that Intermediate shall be permitted to engage in the RCR Transactions.

 (w)    The first sentence of Section 6.23 of the Proposed Amended Credit Agreement is hereby
amended and restated in its entirety to read as follows: 
 Holdings and the Borrower shall not permit any of their respective Restricted
Subsidiaries that is a Loan Party to, (a) maintain Deposit Accounts that are not subject to Account Control Agreements, or (b) maintain securities accounts that are not subject to Account Control Agreements; provided that, the
requirements of the foregoing Section 6.23(a) [Deposit Accounts; Securities Accounts] shall not apply to (i) Deposit Accounts holding exclusively Excluded Funds, (ii) Deposit Accounts and securities accounts to
the extent, and only to the extent, constituting “Excluded Collateral” under Section 2.1(b)(v) [Breakage Costs] or Section 2.1(b)(vi) of the Security Agreement, (iii) petty cash accounts with an amount
not to exceed $250,000 in the aggregate, and (iv) only as to the requirement regarding Account Control Agreements, the Zero Balance Accounts; provided, however, that in the event any Loan Party acquires any Deposit Account or securities
account pursuant to an Acquisition, (y) within 120 days after the date of such Acquisition (or such later date as either of the First Lien Agent or the Collateral Agent may agree to in its sole discretion for the delivery of deposit account
control agreements in respect thereof) Holdings and the Borrower shall deliver, or cause to be delivered, to the Collateral Agent an Account Control Agreement therefor and (z) for so long as any such acquired Deposit Account or securities
account is not subject to an Account Control Agreement, no cash or securities shall be transferred to such acquired Deposit Account or securities account. 

  
 9 

 (x)    Section 7.01(c) of the Proposed Amended Credit Agreement is
hereby amended and restated its entirety as follows: 
 (c) Covenant Breaches. Any Loan Party or any Restricted Subsidiary thereof
shall fail to (i) perform or observe any covenant contained in Section 5.02(a) [Maintenance of Insurance], Section 5.03 [Preservation of Corporate Existence, Etc] (with respect to either
Holdings’, General Partner’s, Intermediate’s or the Borrower’s existence), Section 5.06(i) [Reporting Requirements], Section 5.08 [Collateral Matters; Guaranties],
Section 5.09 [Use of Proceeds], or Article VI [NEGATIVE COVENANTS] of this Agreement or (ii) fail to perform or observe any other term or covenant set forth in this Agreement or in any other Loan Document which is not
covered by clause (i) above or any other provision of this Section 7.01 [Events of Default] if such failure shall remain unremedied for 30 days after the occurrence of such breach or failure; 

(y)    Section 7.01 of the Proposed Amended Credit Agreement is hereby amended by replacing the “.” at the end
of clause (k) with “;” and adding a new clause (l) that shall read in its entirety as follows: 
 (l) Equity of
Borrower. The Administrative Agent shall fail to have an Acceptable Security Interest in 100% of the Equity Interests in the Borrower or the General Partner at any time. 

Section 4. Conditions to Effectiveness. This Agreement shall become effective and enforceable against the parties hereto upon
the receipt by the Agent of this Agreement, duly executed by the Borrower, Holdings, the Guarantors and the Consenting Lenders (the date on which such condition occurs, the “Omnibus Effective Date”). 

Section 5. [Reserved]. 

Section 6. Representations and Warranties. Each Loan Party hereby represents and warrants to the Agent and the Consenting
Lenders that, as of this Agreement, the execution, delivery and performance of this Agreement by such Loan Party has been duly authorized by all requisite limited liability company, partnership or corporate action on the part of such Loan Party, as
applicable, and this Agreement constitutes the valid and binding obligation of such Loan Party enforceable in accordance with its terms, except as the enforceability thereof may be limited by bankruptcy, insolvency or similar laws affecting
creditor’s rights generally. 
 Section 7. Acknowledgments and Agreements. 

(a)    This Agreement is a Loan Document for the purposes of the provisions of the other Loan Documents. 

(b)    Nothing herein shall constitute a waiver or relinquishment of (i) any Default or Event of Default under any of
the Loan Documents, (ii) except as otherwise expressly set forth herein, any of the agreements, terms or conditions contained in any of the Loan Documents, (iii) any rights or remedies of the Agent or any Lender with respect to the Loan
Documents or (iv) the rights of the Agent or any Lender to collect the full amounts owing to them under the Loan Documents. 

  
 10 

 Section 8. Release of Holdings. In connection with the
transactions contemplated by Amendment No. 1 and the Contribution Agreement (as defined in Amendment No. 1), Holdings and the Borrower have requested that Holdings be released from its guaranty obligations under the Loan Documents and its
assets released from the Liens created under the Loan Documents. Subject to the terms hereof and in reliance on the consent provided by the Majority Lenders below, as of the Amendment No. 1 Effective Date, the Consenting Lenders hereby direct
the Agent to release, and the Agent hereby releases and discharges, (a) Holdings from its obligations as a guarantor under the Guaranty and as a grantor under the Security Agreement, and (b) all right, title and interest of Holdings in any
of its Property from the Liens granted under the Security Agreement. The Consenting Lenders expressly consent to the foregoing release and discharge. The foregoing release and discharge by the Agent, and the consent by the Consenting Lenders, are
strictly limited to the extent, and as expressly provided in this Section 8, and are strictly contingent upon the satisfaction of the conditions precedent to the Amendment No. 1 Effective Date. The release, discharge and consent provided
herein is a one-time event and shall not be construed to, or serve to, (i) establish a custom or course of dealing with respect to any of the Loan Documents, (ii) in any way modify, change, impair,
affect, diminish or release the Borrower’s or any other Guarantor’s obligations or liability under the Loan Documents or any other liability the Borrower or any other Guarantor may have to the Agent or any other Secured Party,
(iii) in any way modify, change, impair, affect, diminish or release Holdings from the obligations and liabilities under the Credit Agreement as a party thereto, including Section 6.19 thereof, (iv) in any way modify, change, impair,
affect, diminish or release Holdings from the obligations and liabilities under any Guaranty or supplement to Guaranty and any Security Agreement or supplement to Security Agreement delivered by Holdings after the date hereof, or (v) waive,
limit or condition the Agent’s or any other Lender Party’s rights and remedies under the Loan Documents. 
 Section 9.
Intercreditor Agreement and Revolver Amendment. Strictly for purposes of Sections 7.01(a) and 10.05 of the Intercreditor Agreement, each of the Administrative Agent and the Consenting Lenders (which constitute at least the Majority
Lenders) hereby expressly consent to the following: (a) the terms of the Intercreditor Agreement Amendment, (b) the prepayment of the loans under the First Lien Credit Agreement as described in Section 5(b)(iii)(2) of Amendment
No. 1 and the accrued interest thereon and (c) the amendments to Section 6.21 (Prepayment of Certain Debt and Other Obligations) and Section 6.27 (Second Lien Debt; Senior Unsecured Notes) of the First Lien Credit Agreement
effected by the Revolver Amendment. The Consenting Lenders hereby direct the Agent to execute and deliver the Intercreditor Agreement Amendment. The consent of the Lenders provided herein is strictly limited to the extent provided above and as
expressly provided above. Other than as expressly provided above, nothing contained herein shall be construed to be a waiver of, or a consent to a departure from, the terms of Section 7.01(a) of the Intercreditor Agreement, as amended by the
Intercreditor Agreement Amendment, Section 10.05 of the Intercreditor Agreement, or any other provision in the Loan Documents (including Section 2.05(c) of the Credit Agreement and Section 6.21 of the Credit Agreement). 

Section 10. Consent to Non-Pro Rata Prepayment. Notwithstanding anything to the
contrary set forth Amendment No. 1, each Consenting Lender hereby ratifies its agreement set forth in Section 3 of Amendment No. 1 and agrees to that such repayment in full of all outstanding Advances owed to PensionDanmark
Pensionforsikringsaktieselskab - (PensionDanmark II) (the “Non-Consenting Lender”), together with all accrued interest thereon and any related fees and expenses owed to such Non-Consenting Lender in connection therewith, shall be permitted 

  
 11 

 
notwithstanding anything to the contrary set forth in the Credit Agreement; provided that (i) the aggregate principal amount of such Advances does not exceed $1,500,000 and
(ii) such repayment occurs on or prior to the Amendment No. 1 Effective Date. Each Consenting Lender hereby waives any requirement that the amounts received by the Non-Consenting Lender be shared
equally and ratably with the Consenting Lenders. 
 Section 11. Counterparts. This Agreement may be signed in any number
of counterparts and by different parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which, taken together, constitute one and the same agreement. Delivery of an executed counterpart
of a signature page of this Agreement by facsimile or by e-mail “PDF” copy shall be effective as delivery of a manually executed counterpart of this Agreement. 

Section 12. Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties hereto and
their respective successors and assigns permitted pursuant to the Credit Agreement. 
 Section 13. Invalidity. In the
event that any one or more of the provisions contained in this Agreement shall be held invalid, illegal or unenforceable in any respect under any applicable Legal Requirement, the validity, legality, and enforceability of the remaining provisions
contained herein or therein shall not be affected or impaired thereby. 
 Section 14. Governing Law. This Agreement and
any claim, controversy, dispute or cause of action (whether in contract or tort or otherwise) based upon, arising out of or relating to this Agreement or any other Loan Document (except, as to any other Loan Document, as expressly set forth therein)
and the transactions contemplated hereby and thereby shall be governed by, and construed in accordance with, the law of the State of New York (including Section 5-1401 and
Section 5-1402 of the General Obligations Law of the State of New York), without reference to any other conflicts or choice of law principles thereof. 

Section 15. Entire Agreement. THIS WRITTEN AGREEMENT AND THE OTHER LOAN DOCUMENTS REPRESENT THE FINAL AGREEMENT AMONG
THE PARTIES AND MAY NOT BE CONTRADICTED BY EVIDENCE OF PRIOR, CONTEMPORANEOUS, OR SUBSEQUENT ORAL AGREEMENTS OF THE PARTIES. THERE ARE NO UNWRITTEN ORAL AGREEMENTS AMONG THE PARTIES.  

[SIGNATURES BEGIN ON NEXT PAGE] 

  
 12 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their
respective officers thereunto duly authorized as of the day and year first above written. 
  

			
	BORROWER:
	
	PENN VIRGINIA HOLDINGS, LLC
		
	By:	 	 /s/ Russell T Kelley, Jr.

	Name:	 	Russell T Kelley, Jr.
	Title:	 	Senior Vice President, Chief Financial Officer and Treasurer
	
	HOLDINGS:
	
	PENN VIRGINIA CORPORATION
		
	By:	 	 /s/ Russell T Kelley, Jr.

	Name:	 	Russell T Kelley, Jr.
	Title:	 	Senior Vice President, Chief Financial Officer and Treasurer

  
 Signature Page to Omnibus
Amendment to Credit Agreement (Second Lien) 

 
			
	GUARANTORS:
	
	PENN VIRGINIA OIL & GAS, LLC
	PENN VIRGINIA OIL & GAS GP LLC
	PENN VIRGINIA OIL & GAS LP LLC
	PENN VIRGINIA MC, LLC
	PENN VIRGINIA MC ENERGY L.L.C.
	PENN VIRGINIA MC GATHERING COMPANY L.L.C.
	PENN VIRGINIA MC OPERATING COMPANY L.L.C.
	PENN VIRGINIA RESOURCE HOLDINGS, LLC
		
	By:	 	 /s/ Russell T Kelley,
Jr.            

	Name:	 	Russell T Kelley, Jr.
	Title:	 	Senior Vice President, Chief Financial Officer and Treasurer
	
	PENN VIRGINIA OIL & GAS, L.P.
		 	By: Penn Virginia Oil & Gas GP LLC, its general partner
		
	By:	 	 /s/ Russell T Kelley, Jr.

	Name:	 	Russell T Kelley, Jr.
	Title:	 	Senior Vice President, Chief Financial Officer and Treasurer

  
 Signature Page to Omnibus
Amendment to Credit Agreement (Second Lien) 

 
			
	AGENT:
	
	ARES CAPITAL CORPORATION, as Agent and a Consenting Lender
		
	By:	 	 /s/ Penni Roll

	Name:	 	Penni Roll
	Title:	 	Authorized Signatory

  
 Signature Page to Omnibus
Amendment to Credit Agreement (Second Lien) 

 
			
	LENDERS:
	
	 CION ARES DIVERSIFIED CREDIT FUND, 

as a Consenting Lender

		
	By:	 	 /s/ Joshua Bloomstein

	Name:	 	Joshua Bloomstein
	Title:	 	Authorized Signatory
	
	ARES JASPER FUND, L.P.,
	as a Consenting Lender
		
	By:	 	 /s/ Joshua Bloomstein

	Name:	 	Joshua Bloomstein
	Title:	 	Authorized Signatory
	
	 ARES ND CREDIT STRATEGIES FUND LLC,

as a Consenting Lender

		
	By:	 	 /s/ Joshua Bloomstein

	Name:	 	Joshua Bloomstein
	Title:	 	Authorized Signatory
	
	ARES CREDIT STRATEGIES INSURANCE
	 DEDICATED SERIES INTERESTS OF THE SALI MULTI-SERIES FUND, L.P.,

as a Consenting Lender

		
	By:	 	 /s/ Joshua Bloomstein

	Name:	 	Joshua Bloomstein
	Title:	 	Authorized Signatory
	
	SA REAL ASSETS 20 LIMITED,
	as a Consenting Lender
		
	By:	 	 /s/ Joshua Bloomstein

	Name:	 	Joshua Bloomstein
	Title:	 	Authorized Signatory

  
 Signature Page to Omnibus
Amendment to Credit Agreement (Second Lien) 

 
			
	PREMIA LV1 LTD.,
	as a Consenting Lender
		
	By:	 	 /s/ Joshua Bloomstein            

	Name:	 	Joshua Bloomstein
	Title:	 	Authorized Signatory

  
 Signature Page to Omnibus
Amendment to Credit Agreement (Second Lien) 

 
			
	CONSENTING LENDERS:
	
	GLADWYNE FUNDING LLC,
	as a Consenting Lender
	
	By: FS Energy and Power Fund, its sole member
	By: FS/EIG Advisor, LLC, its investment adviser
		
	By:	 	 /s/ Eric Long

	Name:	 	Eric Long
	Title:	 	Authorized Person
		
	By:	 	 /s/ Andy Jamison

	Name:	 	Andy Jamison
	Title:	 	Authorized Person
	
	HAMILTON FINANCE LLC,
	as a Consenting Lender
	
	By: Guggenheim Partners Investment Management, LLC as Advisor
		
	By:	 	 /s/ Kevin M. Robinson

	Name:	 	Kevin M. Robinson
	Title:	 	Attorney-in-Fact
	
	 EAF COMPLAN II - PRIVATE DEBT,

as a Consenting Lender

	
	By: Guggenheim Partners Investment Management, LLC as Asset Manager
		
	By:	 	 /s/ Kevin M. Robinson

	Name:	 	Kevin M. Robinson
	Title:	 	Attorney-in-Fact

  
 Signature Page to Omnibus
Amendment to Credit Agreement (Second Lien) 

 
			
	 CHEVRON MASTER PENSION TRUST,

as a Consenting Lender

	
	By: Guggenheim Partners Investment Management, LLC as Manager
		
	By:	 	 /s/ Kevin M. Robinson

	Name:	 	Kevin M. Robinson
	Title:	 	Attorney-in-Fact
	
	 GGH US BL AMETRINE SUB-TRUST A SUB-TRUST OF
GUGGENHEIM AMETHYST TRUST,
 as a Consenting Lender

	
	By: Guggenheim Partners Investment Management, LLC as Investment Manager
		
	By:	 	 /s/ Kevin M. Robinson

	Name:	 	Kevin M. Robinson
	Title:	 	Attorney-in-Fact
	
	 GUGGENHEIM ENERGY & INCOME FUND,

as a Consenting Lender

	
	By: Guggenheim Partners Investment Management, LLC as Sub-Adviser
		
	By:	 	 /s/ Kevin M. Robinson

	Name:	 	Kevin M. Robinson
	Title:	 	Attorney-in-Fact

  
 Signature Page to Omnibus
Amendment to Credit Agreement (Second Lien) 

 
			
	 GUGGENHEIM FUNDS TRUST -

GUGGENHEIM FLOATING RATE
 STRATEGIES FUND,

as a Consenting Lender

	
	By: Guggenheim Partners Investment Management, LLC as Investment Adviser
		
	By:	 	 /s/ Kevin M. Robinson

	Name:	 	Kevin M. Robinson
	Title:	 	Attorney-in-Fact
	
	 GUGGENHEIM LOAN MASTER FUND, LTD.,

as a Consenting Lender

	
	By: Guggenheim Partners Investment Management, LLC as Manager
		
	By:	 	 /s/ Kevin M. Robinson

	Name:	 	Kevin M. Robinson
	Title:	 	Attorney-in-Fact
	
	 GUGGENHEIM MM CLO 2018-1, LTD.,

as a Consenting Lender

	
	By: Guggenheim Partners Investment Management, LLC as Collateral Manager
		
	By:	 	 /s/ Kevin M. Robinson

	Name:	 	Kevin M. Robinson
	Title:	 	Attorney-in-Fact
	
	 I.A.M. NATIONAL PENSION FUND,

as a Consenting Lender

	
	By: Guggenheim Partners Investment Management, LLC as Advisor
		
	By:	 	 /s/ Kevin M. Robinson

	Name:	 	Kevin M. Robinson
	Title:	 	Attorney-in-Fact

  
 Signature Page to Omnibus
Amendment to Credit Agreement (Second Lien) 

 
			
	 MAVERICK ENTERPRISES, INC,

as a Consenting Lender

	
	By: Guggenheim Partners Investment Management, LLC as Investment Manager
		
	By:	 	 /s/ Kevin M. Robinson

	Name:	 	Kevin M. Robinson
	Title:	 	Attorney-in-Fact
	
	 GGH LEVERAGED LOAN FUND, A SERIES TRUST OF MYL GLOBAL INVESTMENT TRUST,

as a Consenting Lender

	
	By: Guggenheim Partners Investment Management, LLC as Investment Manager
		
	By:	 	 /s/ Kevin M. Robinson

	Name:	 	Kevin M. Robinson
	Title:	 	Attorney-in-Fact
	
	 GUGGENHEIM DEFENSIVE LOAN FUND,

as a Consenting Lender

	
	By: Guggenheim Partners Investment Management, LLC as Investment Manager
		
	By:	 	 /s/ Kevin M. Robinson

	Name:	 	Kevin M. Robinson
	Title:	 	Attorney-in-Fact

  
 Signature Page to Omnibus
Amendment to Credit Agreement (Second Lien) 

 
			
	 GUGGENHEIM U.S. LOAN FUND,

as a Consenting Lender

	
	For and on behalf of BNY Mellon Trust
	Company (Ireland) Limited under Power of Attorney
		
	By:	 	 /s/ Kevin M. Robinson

	Name:	 	Kevin M. Robinson
	Title:	 	Attorney-in-Fact
	
	 GUGGENHEIM U.S. LOAN FUND II,

as a Consenting Lender

	
	By: Guggenheim Partners Investment Management, LLC as Investment Manager
		
	By:	 	 /s/ Kevin M. Robinson

	Name:	 	Kevin M. Robinson
	Title:	 	Attorney-in-Fact
	
	 GUGGENHEIM U.S. LOAN FUND III,

as a Consenting Lender

	
	By: Guggenheim Partners Investment Management, LLC as Investment Manager
		
	By:	 	 /s/ Kevin M. Robinson

	Name:	 	Kevin M. Robinson
	Title:	 	Attorney-in-Fact
	
	 SONOMA COUNTY EMPLOYEES’ RETIREMENT ASSOCIATION,

as a Consenting Lender

	
	By: Guggenheim Partners Investment Management, LLC as Investment Manager
		
	By:	 	 /s/ Kevin M. Robinson

	Name:	 	Kevin M. Robinson
	Title:	 	Attorney-in-Fact

  
 Signature Page to Omnibus
Amendment to Credit Agreement (Second Lien) 

 
			
	 ZILUX FCP-SIF - ZILUX SENIOR LOANS GLOBAL,

as a Consenting Lender

	
	By: Guggenheim Partners Investment Management, LLC as Investment Manager
		
	By:	 	 /s/ Kevin M. Robinson

	Name:	 	Kevin M. Robinson
	Title:	 	Attorney-in-Fact
	
	 WELLS FARGO BANK, NATIONAL ASSOCIATION,

as a Consenting Lender

		
	By:	 	 /s/ Manish Garg

	Name:	 	Manish Garg
	Title:	 	Vice President
	
	WESTERN ASSET MANAGEMENT COMPANY, LLC,
	as investment manager and agent on behalf of certain COnsenting Lenders
		
	By:	 	 /s/ Adam Wright

	Name:	 	Adam Wright
	Title:	 	Manager, U.S. Legal Affairs

  
 Signature Page to Omnibus
Amendment to Credit Agreement (Second Lien) 

 EXHIBIT A 

Amendment No. 1 to Intercreditor Agreement 

[see attached]Exhibit
10.1

 

SUBSCRIPTION
AGREEMENT

 

OncoCyte
Corporation

15
Cushing

Irvine,
CA 92618

 

Ladies
and Gentlemen:

 

The
undersigned (the “Investor”) hereby confirms and agrees with you as follows:

 

1.
This Subscription Agreement (this “Agreement”) is made as of the date set forth below between OncoCyte
Corporation, a California corporation (the “Company”), and the Investor.

 

2.
The Company is offering to sell and issue up to $25 million of shares, in the aggregate, (the “Shares”)
of the Company’s common stock, no par value per share (the “Common Stock” and such offering, the “Offering”)
at a per Share purchase price of $3.424 (subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations
and other similar transactions of the Common Stock that occur after the date of this Agreement). The Shares being offered have
been registered under the Securities Act of 1933, as amended (the “Securities Act”), pursuant to the Company’s
Registration Statement on Form S-3 (No. 333-231980), including all amendments thereto, the exhibits and any schedules thereto,
the documents otherwise deemed to be a part thereof or included therein by the rules and regulations (the “Rules and
Regulations”) of the U.S. Securities and Exchange Commission (the “Commission”) and any registration
statement relating to the Offering and filed pursuant to Rule 462(b) under the Rules and Regulations (collectively, the “Registration
Statement”). The Investor acknowledges that the Company intends to enter into subscription agreements in substantially
the same form as this Agreement, on the same terms and conditions and prices as hereunder (the “Other Investors’
Agreements”), with certain other accredited investors.

 

3.
As of the Closing (as defined below), and subject to the terms and conditions hereof, the Company and the Investor agree that
the Investor will purchase from the Company and the Company will issue and sell to the Investor such number of Shares (the “Subscription”
and such Shares, the “Investor’s Shares”) as is set forth on the signature page hereto (the “Signature
Page”). The Investor acknowledges that the Offering is being conducted on a best-efforts basis and there is no minimum
offering amount. On the Closing Date, (as defined below), the Investor’s Shares will be delivered on an expedited basis
via The Depository Trust Company’s Deposit and Withdrawal at Custodian service (“DWAC”), registered in
the name of the Investor. This Offering will not clear directly through an underwriter, placement agent or similar broker. Consequently,
the Investor must instruct their individual broker how to settle the transaction.

 

4.
The completion of the purchase and sale of the Shares shall occur at the closing (the “Closing”) which
shall occur on the Trading Day (as defined below) on which all conditions precedent to (i) the Investor’s obligation to
pay the aggregate purchase price for the Investor’s Shares (the “Subscription Amount”) and (ii) the Company’s
obligations to deliver the Investor’s Shares, in each case, have been satisfied or waived, but in no event later than January
26, 2021 (the “Closing Date”). On the Closing Date, (a) the Company shall cause its transfer agent to deliver
on an expedited basis via DWAC the Investor’s Shares and (b) the Subscription Amount will be delivered by or on behalf of
the Investor to the Company by wire transfer pursuant to the Company’s wire instructions delivered to the Investor on Company
letterhead prior to the Closing Date. In the event that the Company is unable to fulfill its obligations hereunder at Closing
by January 29, 2021, Investor shall have the right, but not the obligation, to terminate this Agreement and the Subscription hereunder.
For purposes of this Agreement, “Trading Day” means any day on which the Common Stock is traded on the principal
securities exchange or trading market on which the Common Stock is then traded (the “Exchange”); provided that
“Trading Day” shall not include any day on which the Common Stock is scheduled to trade on such exchange or market
for less than 4.5 hours or any day that the Common Stock is suspended from trading during the final hour of trading on such Exchange
(or if such Exchange does not designate in advance the closing time of trading on such Exchange, then during the hour ending at
4:00 p.m., New York time).

 

    	1

     

    

 

5.
The Registration Statement filed by the Company with the Commission contains a prospectus (the “Base Prospectus”)
and the Company will promptly file with the Commission a final prospectus supplement (the “Prospectus Supplement”
and collectively with the Base Prospectus, the “Prospectus”) with respect to the Registration Statement in
material conformity with the Securities Act, including Rule 424(b) thereunder. The Investor hereby consents to delivery of the
Prospectus in accordance with Rule 172 under the Securities Act.

 

6.
The obligations of the Company to issue and sell the Shares to the Investor shall be subject to: (i) the receipt by the Company
of the Subscription Amount and (ii) the accuracy of the representations and warranties made by the Investor and the fulfillment
of those undertakings of the Investor to be fulfilled prior to the Closing Date.

 

7.
Except as set forth in the SEC Reports (as defined below), the Company hereby makes the following representations, warranties
and covenants to the Investor:

 

(a)
The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
by this Agreement and the Other Investors’ Agreements and otherwise to carry out its obligations hereunder. The execution
and delivery of this Agreement by the Company and the consummation by it of the transactions contemplated hereunder have been
duly authorized by all necessary action on the part of the Company. This Agreement has been duly executed by the Company and,
when delivered in accordance with the terms hereof, will constitute the valid and binding obligation of the Company enforceable
against the Company in accordance with its terms, except as may be limited by any bankruptcy, insolvency, reorganization, moratorium,
fraudulent conveyance or other similar laws affecting the enforcement of creditors’ rights generally or by general principles
of equity.

 

(b)
The Shares are duly authorized and, when issued and paid for in accordance with this Agreement and the Other Investors’
Agreements, will be duly and validly issued, fully paid and nonassessable, free and clear of all liens imposed by the Company.
The Company has reserved from its duly authorized capital stock the maximum number of shares of Common Stock issuable pursuant
to this Agreement. The Company has prepared and filed the Registration Statement in material conformity with the requirements
of the Securities Act, which became effective on June 18, 2019 (the “Effective Date”), and such amendments
and supplements thereto as may have been required to the date of this Agreement. The Registration Statement is effective under
the Securities Act and no stop order preventing or suspending the effectiveness of the Registration Statement or suspending or
preventing the use of the Prospectus has been issued by the Commission and no proceedings for that purpose have been instituted
or, to the knowledge of the Company, are threatened by the Commission. The Company, if required by the rules and regulations of
the Commission, shall file the Prospectus Supplement with the Commission pursuant to Rule 424(b). At the time the Registration
Statement and any amendments thereto became effective, at the date of this Agreement and as of the Closing Date, the Registration
Statement and any amendments thereto conformed and will conform in all material respects to the requirements of the Securities
Act and did not and will not contain any untrue statement of a material fact or omit to state any material fact required to be
stated therein or necessary to make the statements therein not misleading; and the Prospectus and any amendments or supplements
thereto, at time the Prospectus or any amendment or supplement thereto was issued and as of the Closing Date, conformed and will
conform in all material respects to the requirements of the Securities Act and did not and will not contain an untrue statement
of a material fact or omit to state a material fact necessary in order to make the statements therein, in light of the circumstances
under which they were made, not misleading.

 

    	2

     

    

 

(c)
Other than pursuant to the Company’s Equity Distribution Agreement with Piper Sandler & Co., the Company has not
issued any capital stock since its most recently filed periodic report under the Exchange Act, other than pursuant to the exercise
of employee stock options under the Company’s stock option plans, the issuance of shares of Common Stock to employees pursuant
to the Company’s employee stock purchase plans and pursuant to the conversion and/or exercise of any securities convertible
into, exercisable or exchangeable for, or otherwise representing the right to acquire shares of Common Stock (each, a “Common
Stock Equivalent”) outstanding as of the date of the most recently filed SEC Report (as defined below). No Person has
any right of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions
contemplated by this Agreement. Except as otherwise disclosed in the SEC Reports (as defined below) or as a result of the purchase
and sale of the Shares, there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any
character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or
giving any Person any right to subscribe for or acquire, any shares of Common Stock, or contracts, commitments, understandings
or arrangements by which the Company or any of its consolidated subsidiaries (each a “Subsidiary”) is or may
become bound to issue additional shares of Common Stock or Common Stock Equivalents. The issuance and sale of the Shares will
not obligate the Company to issue shares of Common Stock or other securities to any person (other than to investors in this Offering)
and will not result in a right of any holder of Company securities to adjust the exercise, conversion, exchange or reset price
under any of such securities. All of the outstanding shares of capital stock of the Company are duly authorized, validly issued,
fully paid and nonassessable, have been issued in material compliance with all federal and state securities laws, and none of
such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities.
No further approval or authorization of any stockholder or the Board of Directors is required for the issuance and sale of the
Shares. Except as otherwise disclosed in the SEC Reports, there are no stockholders’ agreements, voting agreements or other
similar agreements with respect to the Company’s capital stock to which the Company is a party or, to the knowledge of the
Company, between or among any of the Company’s stockholders.

 

(d)
Since the date of the latest audited financial statements included within any report or definitive proxy or information statements
filed by the Company with the Commission pursuant to Sections 13(a), 13(c), 14, 15(d) or any other provision of or under the Exchange
Act (the “SEC Reports”), except as specifically disclosed in a subsequent SEC Report filed prior to the date
hereof, (i) there has been no event, occurrence or development that has had or that could reasonably be expected to result in
a material adverse effect, or any development that would reasonably be expected to result in a material adverse change, in the
condition, financial or otherwise, or in the results of operations, business, operations or prospects, whether or not arising
from transactions in the ordinary course of business, of the Company and its Subsidiaries, considered as one entity (any such
effect is called a “Material Adverse Effect”), (ii) the Company has not incurred any liabilities (contingent
or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past
practice and (B) liabilities not required to be reflected in the Company’s financial statements pursuant to United States
generally accepted accounting principles (“GAAP”) or disclosed in filings made with the Commission, (iii) the
Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend or distribution of cash
or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital
stock and (v) the Company has not issued any equity securities to any officer, director or affiliate, except pursuant to existing
Company stock option plans. The Company does not have pending before the Commission any request for confidential treatment of
information. Except for the issuance of the Shares contemplated by this Agreement and the Other Investors’ Agreements or
as set forth in the SEC Reports, no event, liability, fact, circumstance, occurrence or development has occurred or exists or
is reasonably expected to occur or exist with respect to the Company or its Subsidiaries or their respective businesses, prospects,
properties, operations, assets or financial condition that would be required to be disclosed by the Company under applicable securities
laws at the time this representation is made or deemed made that has not been publicly disclosed at least 1 Trading Day prior
to the date that this representation is made.

 

(e)
The Company shall (i) by the Disclosure Time (as defined below), issue a press release disclosing the material terms of the
transactions contemplated hereby and (ii) make such other filings and notices in the manner and time required by the Commission
with respect to the transactions contemplated hereby. The Company shall not identify the Investor by name in any press release
or public filing, or otherwise publicly disclose the Investor’s name, without the Investor’s prior written consent,
unless required by law or the rules and regulations of any self-regulatory organization or exchange to which the Company or its
securities are subject. For the purposes of this Agreement, “Disclosure Time” means, (i) if this Agreement
is signed on a day that is not a Trading Day or after 9:00 a.m. (New York City time) and before midnight (New York City time)
on any Trading Day, 9:01 a.m. (New York City time) on the Trading Day immediately following the date hereof, and (ii) if this
Agreement is signed between midnight (New York City time) and 9:00 a.m. (New York City time) on any Trading Day, no later than
9:01 a.m. (New York City time) on the date hereof.

 

    	3

     

    

 

(f)
The making, execution and performance of this Agreement by the Company and the consummation of the transactions contemplated
herein will not conflict with or result in a breach or violation of any of the terms and provisions of, or constitute a default
under, (i) the charter, bylaws or other organizational documents of the Company, as applicable, (ii) any law, order, rule, regulation,
writ, injunction, judgment or decree of any court, administrative agency, regulatory body, government or governmental agency or
body, domestic or foreign, having jurisdiction over the Company or its properties (including federal and state securities laws
and regulations and the rules and regulations of the NYSE American or other applicable Exchange) or (iii) conflict with, or constitute
a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights
of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the Company or any
of its Subsidiaries is a party, except for any conflict, breach, violation or default which is not reasonably likely to have a
material adverse effect on the Company, its Subsidiaries or any property or asset of the Company or any of its Subsidiaries or
the Company’s performance of its obligations hereunder or the consummation of the transactions contemplated hereby.

 

(g)
The Company is not required to obtain any consent, authorization or order of, or make any filing or registration with, any
court, governmental agency or any regulatory or self-regulatory agency or any other Person in order for it to execute, deliver
or perform any of its obligations hereunder in accordance with the terms hereof, other than (i) as may be required under the Securities
Act, (ii) any necessary qualification of the Shares under the securities or blue sky laws of the various jurisdictions in which
the Shares are being offered and (iii) under the rules and regulations of the Financial Industry Regulatory Authority (“FINRA”)
or the NYSE American. All consents, authorizations, orders, filings and registrations which the Company is required to obtain
pursuant to the preceding sentence will be obtained or effected on or prior to the Closing Date, and the Company and its Subsidiaries
are unaware of any facts or circumstances which might prevent the Company from obtaining or effecting any of the registration,
application or filings pursuant to the preceding sentence.

 

(h)
The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly, any action designed
to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale
or resale of any of the Shares, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases of, any of the
Shares, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities
of the Company.

 

8.
The Investor hereby makes the following representations, warranties and covenants to the Company:

 

(a)
The Investor represents that (i) it has received or had full access to the Base Prospectus, as well as the Company’s
periodic reports and other information incorporated by reference therein, prior to or in connection with its receipt of this Agreement,
(ii) it is knowledgeable, sophisticated and experienced in making, and is qualified to make, decisions with respect to investments
in securities representing an investment decision like that involved in the purchase of the Shares, and (iii) it does not have
any agreement or understanding, directly or indirectly, with any person or entity to distribute any of the Shares.

 

(b)
The Investor has the requisite power and authority to enter into this Agreement and to consummate the transactions contemplated
hereby. The execution and delivery of this Agreement by the Investor and the consummation by it of the transactions contemplated
hereunder have been duly authorized by all necessary action on the part of the Investor. This Agreement has been executed by the
Investor and, when delivered in accordance with the terms hereof, will constitute a valid and binding obligation of the Investor
enforceable against the Investor in accordance with its terms, except as enforceability may be limited by applicable bankruptcy,
insolvency, reorganization, moratorium or similar laws affecting creditors’ and contracting parties’ rights generally
and except as enforceability may be subject to general principles of equity (regardless of whether such enforceability is considered
in a proceeding in equity or at law).

 

    	4

     

    

 

(c)
The Investor understands that nothing in this Agreement or any other materials presented to the Investor in connection with
the purchase and sale of the Shares constitutes legal, tax or investment advice. The Investor has consulted such legal, tax and
investment advisors as it, in its sole discretion, has deemed necessary or appropriate in connection with its purchase of the
Shares.

 

(d)
The making, execution and performance of this Agreement by the Investor and the consummation of the transactions contemplated
herein will not conflict with or result in a breach or violation of any of the terms and provisions of, or constitute a default
under, (i) the charter, bylaws or other organizational documents of such Investor, as applicable, or (ii) any law, order, rule,
regulation, writ, injunction, judgment or decree of any court, administrative agency, regulatory body, government or governmental
agency or body, domestic or foreign, having jurisdiction over such Investor or its properties, except for any conflict, breach,
violation or default which is not reasonably likely to have a material adverse effect on such Investor’s performance of
its obligations hereunder or the consummation of the transactions contemplated hereby.

 

(e)
The Investor is a party to a confidentiality agreement with the Company, pursuant to which it will maintain the confidentiality
of, and not use in any way (including not trading on the basis of) all information acquired in connection with the transactions
contemplated herein prior to the public disclosure of that information by the Company.

 

(f)
Neither the Investor nor any Person acting on behalf of, or pursuant to any understanding with or based upon any information
received from, the Investor has, directly or indirectly, engaged in any purchases or sales of the securities of the Company (including,
without limitation, any Short Sales involving the Company’s securities) since the time that the Investor first discussed
the transactions contemplated hereby with the Company. “Short Sales” include, without limitation, all “short
sales” as defined in Rule 200 promulgated under Regulation SHO under the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), whether or not against the box, and all types of direct and indirect stock pledges, forward
sale contracts, options, puts, calls, short sales, swaps, “put equivalent positions” (as defined in Rule 16a-1(h)
under the Exchange Act) and similar arrangements (including on a total return basis), and sales and other transactions through
non-U.S. broker dealers or foreign regulated brokers. The Investor covenants that neither it, nor any Person acting on behalf
of, or pursuant to any understanding with or based upon any information received from, will engage in any purchases or sales of
the securities of the Company (including Short Sales) prior to the time that the Company confirms to the Purchaser in writing
that all material nonpublic information has been publicly disclosed.

 

(g)
The Investor represents that, except as set forth below, (i) it has had no position, office or other material relationship
within the past three years with the Company or persons known to it to be affiliates of the Company, (ii) it is not a, and it
has no direct or indirect association with any, FINRA member or an Associated Person (as such term is defined under the FINRA
Membership and Registration Rules Section 1011) as of the date hereof, and (iii) neither it nor any group of investors (as identified
in a public filing made with the Commission) of which it is a member, acquired, or obtained the right to acquire, 20% or more
of the Common Stock (or securities convertible or exercisable for Common Stock) or the voting power of the Company on a post-transaction
basis. Exceptions:

 

Those
matters disclosed in regulatory filings by the Investor and its affiliates

(If
no exceptions, write “none.” If left blank, response will be deemed to be “none.”)

 

    	5

     

    

 

(h)
The Investor acknowledges that it has had the opportunity to review this Agreement (including all exhibits and schedules thereto)
and the SEC Reports and has been afforded (i) the opportunity to ask such questions as it has deemed necessary of representatives
of the Company and to receive answers from such representatives concerning the terms and conditions of the offering of the Shares
and the merits and risks of investing in the Shares; (ii) access to information about the Company and its financial condition,
results of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and
(iii) the opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable effort
or expense that is necessary to make an informed investment decision with respect to the investment.

 

9.
Except as expressly set forth in this Agreement to the contrary, each party shall pay the fees and expenses of its advisers,
counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation,
execution, delivery and performance of this Agreement.

 

10.
Notwithstanding any investigation made by any party to this Agreement, all covenants, agreements, representations and warranties
made by the Company and the Investor herein will survive the execution of this Agreement, the delivery to the Investor of the
Shares being purchased and the payment therefor.

 

11.
This Agreement may not be modified or amended except pursuant to an instrument in writing signed by the Company and the Investor.

 

12.
In case any provision contained in this Agreement should be invalid, illegal or unenforceable in any respect, the validity,
legality and enforceability of the remaining provisions contained herein will not in any way be affected or impaired thereby.

 

13.
This Agreement will be governed by, and construed in accordance with, the internal laws of the State of New York, without
giving effect to the principles of conflicts of law that would require the application of the laws of any other jurisdiction.

 

14.
This Agreement may be executed in counterparts, each of which will constitute an original, but all of which, when taken together,
will constitute but one instrument, and will become effective when counterparts have been signed by each party hereto and delivered
to the other party, and such counterparts may be delivered electronically.

 

15.
This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and
is not for the benefit of, nor may any provision hereof be enforced by, any other Person.

 

16.
The Investor acknowledges and agrees that such Investor’s receipt of the Company’s counterpart to this Agreement
shall constitute written confirmation of the Company’s sale of Shares to such Investor.

 

[SIGNATURE
PAGES FOLLOW]

 

    	6

     

    

 

INVESTOR
SIGNATURE PAGE

 

Number
of Shares: 1,810,750

 

Purchase
Price Per Share: $3.424

 

Aggregate
Purchase Price: $6,200,008.00

 

Please
confirm that the foregoing correctly sets forth the agreement between us by signing in the space provided below for that purpose.

 

Dated
as of January 20, 2021

 

	INVESTOR	 
	 	 	 
	By:	/s/
    Efrem Kamen	 
	Print
    Name:	Eferm Kamen	 
	Title:	Managing
    Member of Pura Vida Investments, LLC in its capacity as investment manager to Investor

Name
in which Securities are to be registered: Segregated Account Highmark Long/Short Equity 20

Mailing
Address: c/o Pura Vida Investments, LLC, 150 East 52nd Street, Suite 32001, New York, NY, 10022

 

Facsimile
Number: c/o Pura Vida Investments:

 

Email
Address:

 

Taxpayer
Identification Number:

 

Manner
of Settlement of the Shares: DWAC (The Shares will be sent from the Company’s transfer agent, American Stock Transfer &
Trust Company, by DWAC to your prime broker. You must contact your prime broker and ask them to initiate the DWAC
or you will not receive the Shares. The Shares will only be released after the Company’s receipt of the funds.)

 

	Name
                                         of DTC Participant (broker-dealer at which the account or accounts to be credited with
                                         the Shares are maintained)
	 	 

        Please
        see the attached instructions

	 	 	 
	DTC
                                         Participant Number
	 	__________________________
	 	 	 
	Name
                                         of Account at DTC Participant being credited with the Shares
	 	 

         __________________________

	 	 	 
	Account
                                         Number at DTC Participant being credited with the Shares
	 	 

        __________________________ 

 

    	7

     

    

 

Agreed
and Accepted this 20th day of January, 2021:

 

	OncoCyte
    Corporation	 
	 	 	 
	By:	/s/
    Mitch Levine     	 
	Name:
    	Mitch
    Levine	 
	Title:
    	CFO	 

 

Sales
of the Shares purchased hereunder were made pursuant to a registration statement or in a transaction in which a final prospectus
would have been required to have been delivered in the absence of Rule 172 promulgated under the Securities Act.

 

    	8

     

    

 

SUBSCRIPTION
AGREEMENT

 

OncoCyte
Corporation

15
Cushing

Irvine,
CA 92618

 

Ladies
and Gentlemen:

 

The
undersigned (the “Investor”) hereby confirms and agrees with you as follows:

 

1.
This Subscription Agreement (this “Agreement”) is made as of the date set forth below between OncoCyte
Corporation, a California corporation (the “Company”), and the Investor.

 

2.
The Company is offering to sell and issue up to $25 million of shares, in the aggregate, (the “Shares”)
of the Company’s common stock, no par value per share (the “Common Stock” and such offering, the “Offering”)
at a per Share purchase price of $3.424 (subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations
and other similar transactions of the Common Stock that occur after the date of this Agreement). The Shares being offered have
been registered under the Securities Act of 1933, as amended (the “Securities Act”), pursuant to the Company’s
Registration Statement on Form S-3 (No. 333-231980), including all amendments thereto, the exhibits and any schedules thereto,
the documents otherwise deemed to be a part thereof or included therein by the rules and regulations (the “Rules and
Regulations”) of the U.S. Securities and Exchange Commission (the “Commission”) and any registration
statement relating to the Offering and filed pursuant to Rule 462(b) under the Rules and Regulations (collectively, the “Registration
Statement”). The Investor acknowledges that the Company intends to enter into subscription agreements in substantially
the same form as this Agreement, on the same terms and conditions and prices as hereunder (the “Other Investors’
Agreements”), with certain other accredited investors.

 

3.
As of the Closing (as defined below), and subject to the terms and conditions hereof, the Company and the Investor agree that
the Investor will purchase from the Company and the Company will issue and sell to the Investor such number of Shares (the “Subscription”
and such Shares, the “Investor’s Shares”) as is set forth on the signature page hereto (the “Signature
Page”). The Investor acknowledges that the Offering is being conducted on a best-efforts basis and there is no minimum
offering amount. On the Closing Date, (as defined below), the Investor’s Shares will be delivered on an expedited basis
via The Depository Trust Company’s Deposit and Withdrawal at Custodian service (“DWAC”), registered in
the name of the Investor. This Offering will not clear directly through an underwriter, placement agent or similar broker. Consequently,
the Investor must instruct their individual broker how to settle the transaction.

 

4.
The completion of the purchase and sale of the Shares shall occur at the closing (the “Closing”) which
shall occur on the Trading Day (as defined below) on which all conditions precedent to (i) the Investor’s obligation to
pay the aggregate purchase price for the Investor’s Shares (the “Subscription Amount”) and (ii) the Company’s
obligations to deliver the Investor’s Shares, in each case, have been satisfied or waived, but in no event later than January
26, 2021 (the “Closing Date”). On the Closing Date, (a) the Company shall cause its transfer agent to deliver
on an expedited basis via DWAC the Investor’s Shares and (b) the Subscription Amount will be delivered by or on behalf of
the Investor to the Company by wire transfer pursuant to the Company’s wire instructions delivered to the Investor on Company
letterhead prior to the Closing Date. In the event that the Company is unable to fulfill its obligations hereunder at Closing
by January 29, 2021, Investor shall have the right, but not the obligation, to terminate this Agreement and the Subscription hereunder.
For purposes of this Agreement, “Trading Day” means any day on which the Common Stock is traded on the principal
securities exchange or trading market on which the Common Stock is then traded (the “Exchange”); provided that
“Trading Day” shall not include any day on which the Common Stock is scheduled to trade on such exchange or market
for less than 4.5 hours or any day that the Common Stock is suspended from trading during the final hour of trading on such Exchange
(or if such Exchange does not designate in advance the closing time of trading on such Exchange, then during the hour ending at
4:00 p.m., New York time).

 

    	1

     

    

 

5.
The Registration Statement filed by the Company with the Commission contains a prospectus (the “Base Prospectus”)
and the Company will promptly file with the Commission a final prospectus supplement (the “Prospectus Supplement”
and collectively with the Base Prospectus, the “Prospectus”) with respect to the Registration Statement in
material conformity with the Securities Act, including Rule 424(b) thereunder. The Investor hereby consents to delivery of the
Prospectus in accordance with Rule 172 under the Securities Act.

 

6.
The obligations of the Company to issue and sell the Shares to the Investor shall be subject to: (i) the receipt by the Company
of the Subscription Amount and (ii) the accuracy of the representations and warranties made by the Investor and the fulfillment
of those undertakings of the Investor to be fulfilled prior to the Closing Date.

 

7.
Except as set forth in the SEC Reports (as defined below), the Company hereby makes the following representations, warranties
and covenants to the Investor:

 

(a)
The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
by this Agreement and the Other Investors’ Agreements and otherwise to carry out its obligations hereunder. The execution
and delivery of this Agreement by the Company and the consummation by it of the transactions contemplated hereunder have been
duly authorized by all necessary action on the part of the Company. This Agreement has been duly executed by the Company and,
when delivered in accordance with the terms hereof, will constitute the valid and binding obligation of the Company enforceable
against the Company in accordance with its terms, except as may be limited by any bankruptcy, insolvency, reorganization, moratorium,
fraudulent conveyance or other similar laws affecting the enforcement of creditors’ rights generally or by general principles
of equity.

 

(b)
The Shares are duly authorized and, when issued and paid for in accordance with this Agreement and the Other Investors’
Agreements, will be duly and validly issued, fully paid and nonassessable, free and clear of all liens imposed by the Company.
The Company has reserved from its duly authorized capital stock the maximum number of shares of Common Stock issuable pursuant
to this Agreement. The Company has prepared and filed the Registration Statement in material conformity with the requirements
of the Securities Act, which became effective on June 18, 2019 (the “Effective Date”), and such amendments
and supplements thereto as may have been required to the date of this Agreement. The Registration Statement is effective under
the Securities Act and no stop order preventing or suspending the effectiveness of the Registration Statement or suspending or
preventing the use of the Prospectus has been issued by the Commission and no proceedings for that purpose have been instituted
or, to the knowledge of the Company, are threatened by the Commission. The Company, if required by the rules and regulations of
the Commission, shall file the Prospectus Supplement with the Commission pursuant to Rule 424(b). At the time the Registration
Statement and any amendments thereto became effective, at the date of this Agreement and as of the Closing Date, the Registration
Statement and any amendments thereto conformed and will conform in all material respects to the requirements of the Securities
Act and did not and will not contain any untrue statement of a material fact or omit to state any material fact required to be
stated therein or necessary to make the statements therein not misleading; and the Prospectus and any amendments or supplements
thereto, at time the Prospectus or any amendment or supplement thereto was issued and as of the Closing Date, conformed and will
conform in all material respects to the requirements of the Securities Act and did not and will not contain an untrue statement
of a material fact or omit to state a material fact necessary in order to make the statements therein, in light of the circumstances
under which they were made, not misleading.

 

    	2

     

    

 

(c)
Other than pursuant to the Company’s Equity Distribution Agreement with Piper Sandler & Co., the Company has not
issued any capital stock since its most recently filed periodic report under the Exchange Act, other than pursuant to the exercise
of employee stock options under the Company’s stock option plans, the issuance of shares of Common Stock to employees pursuant
to the Company’s employee stock purchase plans and pursuant to the conversion and/or exercise of any securities convertible
into, exercisable or exchangeable for, or otherwise representing the right to acquire shares of Common Stock (each, a “Common
Stock Equivalent”) outstanding as of the date of the most recently filed SEC Report (as defined below). No Person has
any right of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions
contemplated by this Agreement. Except as otherwise disclosed in the SEC Reports (as defined below) or as a result of the purchase
and sale of the Shares, there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any
character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or
giving any Person any right to subscribe for or acquire, any shares of Common Stock, or contracts, commitments, understandings
or arrangements by which the Company or any of its consolidated subsidiaries (each a “Subsidiary”) is or may
become bound to issue additional shares of Common Stock or Common Stock Equivalents. The issuance and sale of the Shares will
not obligate the Company to issue shares of Common Stock or other securities to any person (other than to investors in this Offering)
and will not result in a right of any holder of Company securities to adjust the exercise, conversion, exchange or reset price
under any of such securities. All of the outstanding shares of capital stock of the Company are duly authorized, validly issued,
fully paid and nonassessable, have been issued in material compliance with all federal and state securities laws, and none of
such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities.
No further approval or authorization of any stockholder or the Board of Directors is required for the issuance and sale of the
Shares. Except as otherwise disclosed in the SEC Reports, there are no stockholders’ agreements, voting agreements or other
similar agreements with respect to the Company’s capital stock to which the Company is a party or, to the knowledge of the
Company, between or among any of the Company’s stockholders.

 

(d)
Since the date of the latest audited financial statements included within any report or definitive proxy or information statements
filed by the Company with the Commission pursuant to Sections 13(a), 13(c), 14, 15(d) or any other provision of or under the Exchange
Act (the “SEC Reports”), except as specifically disclosed in a subsequent SEC Report filed prior to the date
hereof, (i) there has been no event, occurrence or development that has had or that could reasonably be expected to result in
a material adverse effect, or any development that would reasonably be expected to result in a material adverse change, in the
condition, financial or otherwise, or in the results of operations, business, operations or prospects, whether or not arising
from transactions in the ordinary course of business, of the Company and its Subsidiaries, considered as one entity (any such
effect is called a “Material Adverse Effect”), (ii) the Company has not incurred any liabilities (contingent
or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past
practice and (B) liabilities not required to be reflected in the Company’s financial statements pursuant to United States
generally accepted accounting principles (“GAAP”) or disclosed in filings made with the Commission, (iii) the
Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend or distribution of cash
or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital
stock and (v) the Company has not issued any equity securities to any officer, director or affiliate, except pursuant to existing
Company stock option plans. The Company does not have pending before the Commission any request for confidential treatment of
information. Except for the issuance of the Shares contemplated by this Agreement and the Other Investors’ Agreements or
as set forth in the SEC Reports, no event, liability, fact, circumstance, occurrence or development has occurred or exists or
is reasonably expected to occur or exist with respect to the Company or its Subsidiaries or their respective businesses, prospects,
properties, operations, assets or financial condition that would be required to be disclosed by the Company under applicable securities
laws at the time this representation is made or deemed made that has not been publicly disclosed at least 1 Trading Day prior
to the date that this representation is made.

 

(e)
The Company shall (i) by the Disclosure Time (as defined below), issue a press release disclosing the material terms of the
transactions contemplated hereby and (ii) make such other filings and notices in the manner and time required by the Commission
with respect to the transactions contemplated hereby. The Company shall not identify the Investor by name in any press release
or public filing, or otherwise publicly disclose the Investor’s name, without the Investor’s prior written consent,
unless required by law or the rules and regulations of any self-regulatory organization or exchange to which the Company or its
securities are subject. For the purposes of this Agreement, “Disclosure Time” means, (i) if this Agreement
is signed on a day that is not a Trading Day or after 9:00 a.m. (New York City time) and before midnight (New York City time)
on any Trading Day, 9:01 a.m. (New York City time) on the Trading Day immediately following the date hereof, and (ii) if this
Agreement is signed between midnight (New York City time) and 9:00 a.m. (New York City time) on any Trading Day, no later than
9:01 a.m. (New York City time) on the date hereof.

 

    	3

     

    

 

(f)
The making, execution and performance of this Agreement by the Company and the consummation of the transactions contemplated
herein will not conflict with or result in a breach or violation of any of the terms and provisions of, or constitute a default
under, (i) the charter, bylaws or other organizational documents of the Company, as applicable, (ii) any law, order, rule, regulation,
writ, injunction, judgment or decree of any court, administrative agency, regulatory body, government or governmental agency or
body, domestic or foreign, having jurisdiction over the Company or its properties (including federal and state securities laws
and regulations and the rules and regulations of the NYSE American or other applicable Exchange) or (iii) conflict with, or constitute
a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights
of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the Company or any
of its Subsidiaries is a party, except for any conflict, breach, violation or default which is not reasonably likely to have a
material adverse effect on the Company, its Subsidiaries or any property or asset of the Company or any of its Subsidiaries or
the Company’s performance of its obligations hereunder or the consummation of the transactions contemplated hereby.

 

(g)
The Company is not required to obtain any consent, authorization or order of, or make any filing or registration with, any
court, governmental agency or any regulatory or self-regulatory agency or any other Person in order for it to execute, deliver
or perform any of its obligations hereunder in accordance with the terms hereof, other than (i) as may be required under the Securities
Act, (ii) any necessary qualification of the Shares under the securities or blue sky laws of the various jurisdictions in which
the Shares are being offered and (iii) under the rules and regulations of the Financial Industry Regulatory Authority (“FINRA”)
or the NYSE American. All consents, authorizations, orders, filings and registrations which the Company is required to obtain
pursuant to the preceding sentence will be obtained or effected on or prior to the Closing Date, and the Company and its Subsidiaries
are unaware of any facts or circumstances which might prevent the Company from obtaining or effecting any of the registration,
application or filings pursuant to the preceding sentence.

 

(h)
The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly, any action designed
to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale
or resale of any of the Shares, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases of, any of the
Shares, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities
of the Company.

 

8.
The Investor hereby makes the following representations, warranties and covenants to the Company:

 

(a)
The Investor represents that (i) it has received or had full access to the Base Prospectus, as well as the Company’s
periodic reports and other information incorporated by reference therein, prior to or in connection with its receipt of this Agreement,
(ii) it is knowledgeable, sophisticated and experienced in making, and is qualified to make, decisions with respect to investments
in securities representing an investment decision like that involved in the purchase of the Shares, and (iii) it does not have
any agreement or understanding, directly or indirectly, with any person or entity to distribute any of the Shares.

 

(b)
The Investor has the requisite power and authority to enter into this Agreement and to consummate the transactions contemplated
hereby. The execution and delivery of this Agreement by the Investor and the consummation by it of the transactions contemplated
hereunder have been duly authorized by all necessary action on the part of the Investor. This Agreement has been executed by the
Investor and, when delivered in accordance with the terms hereof, will constitute a valid and binding obligation of the Investor
enforceable against the Investor in accordance with its terms, except as enforceability may be limited by applicable bankruptcy,
insolvency, reorganization, moratorium or similar laws affecting creditors’ and contracting parties’ rights generally
and except as enforceability may be subject to general principles of equity (regardless of whether such enforceability is considered
in a proceeding in equity or at law).

 

    	4

     

    

 

(c)
The Investor understands that nothing in this Agreement or any other materials presented to the Investor in connection with
the purchase and sale of the Shares constitutes legal, tax or investment advice. The Investor has consulted such legal, tax and
investment advisors as it, in its sole discretion, has deemed necessary or appropriate in connection with its purchase of the
Shares.

 

(d)
The making, execution and performance of this Agreement by the Investor and the consummation of the transactions contemplated
herein will not conflict with or result in a breach or violation of any of the terms and provisions of, or constitute a default
under, (i) the charter, bylaws or other organizational documents of such Investor, as applicable, or (ii) any law, order, rule,
regulation, writ, injunction, judgment or decree of any court, administrative agency, regulatory body, government or governmental
agency or body, domestic or foreign, having jurisdiction over such Investor or its properties, except for any conflict, breach,
violation or default which is not reasonably likely to have a material adverse effect on such Investor’s performance of
its obligations hereunder or the consummation of the transactions contemplated hereby.

 

(e)
The Investor is a party to a confidentiality agreement with the Company, pursuant to which it will maintain the confidentiality
of, and not use in any way (including not trading on the basis of) all information acquired in connection with the transactions
contemplated herein prior to the public disclosure of that information by the Company.

 

(f)
Neither the Investor nor any Person acting on behalf of, or pursuant to any understanding with or based upon any information
received from, the Investor has, directly or indirectly, engaged in any purchases or sales of the securities of the Company (including,
without limitation, any Short Sales involving the Company’s securities) since the time that the Investor first discussed
the transactions contemplated hereby with the Company. “Short Sales” include, without limitation, all “short
sales” as defined in Rule 200 promulgated under Regulation SHO under the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), whether or not against the box, and all types of direct and indirect stock pledges, forward
sale contracts, options, puts, calls, short sales, swaps, “put equivalent positions” (as defined in Rule 16a-1(h)
under the Exchange Act) and similar arrangements (including on a total return basis), and sales and other transactions through
non-U.S. broker dealers or foreign regulated brokers. The Investor covenants that neither it, nor any Person acting on behalf
of, or pursuant to any understanding with or based upon any information received from, will engage in any purchases or sales of
the securities of the Company (including Short Sales) prior to the time that the Company confirms to the Purchaser in writing
that all material nonpublic information has been publicly disclosed.

 

(g)
The Investor represents that, except as set forth below, (i) it has had no position, office or other material relationship
within the past three years with the Company or persons known to it to be affiliates of the Company, (ii) it is not a, and it
has no direct or indirect association with any, FINRA member or an Associated Person (as such term is defined under the FINRA
Membership and Registration Rules Section 1011) as of the date hereof, and (iii) neither it nor any group of investors (as identified
in a public filing made with the Commission) of which it is a member, acquired, or obtained the right to acquire, 20% or more
of the Common Stock (or securities convertible or exercisable for Common Stock) or the voting power of the Company on a post-transaction
basis. Exceptions:

 

Those
matters disclosed in regulatory filings by the Investor and its affiliates

(If
no exceptions, write “none.” If left blank, response will be deemed to be “none.”)

 

    	5

     

    

 

(h)
The Investor acknowledges that it has had the opportunity to review this Agreement (including all exhibits and schedules thereto)
and the SEC Reports and has been afforded (i) the opportunity to ask such questions as it has deemed necessary of representatives
of the Company and to receive answers from such representatives concerning the terms and conditions of the offering of the Shares
and the merits and risks of investing in the Shares; (ii) access to information about the Company and its financial condition,
results of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and
(iii) the opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable effort
or expense that is necessary to make an informed investment decision with respect to the investment.

 

9.
Except as expressly set forth in this Agreement to the contrary, each party shall pay the fees and expenses of its advisers,
counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation,
execution, delivery and performance of this Agreement.

 

10.
Notwithstanding any investigation made by any party to this Agreement, all covenants, agreements, representations and warranties
made by the Company and the Investor herein will survive the execution of this Agreement, the delivery to the Investor of the
Shares being purchased and the payment therefor.

 

11.
This Agreement may not be modified or amended except pursuant to an instrument in writing signed by the Company and the Investor.

 

12.
In case any provision contained in this Agreement should be invalid, illegal or unenforceable in any respect, the validity,
legality and enforceability of the remaining provisions contained herein will not in any way be affected or impaired thereby.

 

13.
This Agreement will be governed by, and construed in accordance with, the internal laws of the State of New York, without
giving effect to the principles of conflicts of law that would require the application of the laws of any other jurisdiction.

 

14.
This Agreement may be executed in counterparts, each of which will constitute an original, but all of which, when taken together,
will constitute but one instrument, and will become effective when counterparts have been signed by each party hereto and delivered
to the other party, and such counterparts may be delivered electronically.

 

15.
This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and
is not for the benefit of, nor may any provision hereof be enforced by, any other Person.

 

16.
The Investor acknowledges and agrees that such Investor’s receipt of the Company’s counterpart to this Agreement
shall constitute written confirmation of the Company’s sale of Shares to such Investor.

 

[SIGNATURE
PAGES FOLLOW]

 

    	6

     

    

 

INVESTOR
SIGNATURE PAGE

 

Number
of Shares: 2,570,100

 

Purchase
Price Per Share: $3.424

 

Aggregate
Purchase Price: $8,800,022.40

 

Please
confirm that the foregoing correctly sets forth the agreement between us by signing in the space provided below for that purpose.

 

Dated
as of January 20, 2021

 

INVESTOR

 

	By:
    	/s/
    Efrem Kamen 	 
	Print
    Name:	Eferm
    Kamen	 
	Title:
    	Managing
    Member of Pura Vida Investments, LLC in its capacity as investment manager to Investor

Name
in which Securities are to be registered: Pura Vida Master Fund, Ltd.

Mailing
Address: c/o Pura Vida Investments, LLC, 150 East 52nd Street, Suite 32001, New York, NY, 10022

 

Facsimile
Number: c/o Pura Vida Investments:

 

Email
Address:

 

Taxpayer
Identification Number:

 

Manner
of Settlement of the Shares: DWAC (The Shares will be sent from the Company’s transfer agent, American Stock Transfer &
Trust Company, by DWAC to your prime broker. You must contact your prime broker and ask them to initiate the DWAC
or you will not receive the Shares. The Shares will only be released after the Company’s receipt of the funds.)

 

	Name
    of DTC Participant (broker-dealer at which the account or accounts to be credited with the Shares are maintained)	 	Please
    see the attached instructions
	 	 	 
	DTC
    Participant Number	 	__________________________
	 	 	 
	Name
    of Account at DTC Participant being credited with the Shares	 	__________________________
	 	 	 
	Account
                                         Number at DTC Participant being credited with the Shares
	 	__________________________

 

    	7

     

    

 

Agreed
and Accepted this 20th day of January, 2021:

 

OncoCyte
Corporation

 

	By:	/s/
    Mitch Levine 	 
	Name:	Mitch
    Levine	 
	Title:	CFO	 

 

Sales
of the Shares purchased hereunder were made pursuant to a registration statement or in a transaction in which a final prospectus
would have been required to have been delivered in the absence of Rule 172 promulgated under the Securities Act.

 

    	8

     

    

 

SUBSCRIPTION
AGREEMENT

 

OncoCyte
Corporation

15
Cushing

Irvine,
CA 92618

 

Ladies
and Gentlemen:

 

The
undersigned (the “Investor”) hereby confirms and agrees with you as follows:

 

1.
This Subscription Agreement (this “Agreement”) is made as of the date set forth below between OncoCyte
Corporation, a California corporation (the “Company”), and the Investor.

 

2.
The Company is offering to sell and issue up to $25 million of shares, in the aggregate, (the “Shares”)
of the Company’s common stock, no par value per share (the “Common Stock” and such offering, the “Offering”)
at a per Share purchase price of $3.424 (subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations
and other similar transactions of the Common Stock that occur after the date of this Agreement). The Shares being offered have
been registered under the Securities Act of 1933, as amended (the “Securities Act”), pursuant to the Company’s
Registration Statement on Form S-3 (No. 333-231980), including all amendments thereto, the exhibits and any schedules thereto,
the documents otherwise deemed to be a part thereof or included therein by the rules and regulations (the “Rules and
Regulations”) of the U.S. Securities and Exchange Commission (the “Commission”) and any registration
statement relating to the Offering and filed pursuant to Rule 462(b) under the Rules and Regulations (collectively, the “Registration
Statement”). The Investor acknowledges that the Company intends to enter into subscription agreements in substantially
the same form as this Agreement, on the same terms and conditions and prices as hereunder (the “Other Investors’
Agreements”), with certain other accredited investors.

 

3.
As of the Closing (as defined below), and subject to the terms and conditions hereof, the Company and the Investor agree that
the Investor will purchase from the Company and the Company will issue and sell to the Investor such number of Shares (the “Subscription”
and such Shares, the “Investor’s Shares”) as is set forth on the signature page hereto (the “Signature
Page”). The Investor acknowledges that the Offering is being conducted on a best-efforts basis and there is no minimum
offering amount. On the Closing Date, (as defined below), the Investor’s Shares will be delivered on an expedited basis
via The Depository Trust Company’s Deposit and Withdrawal at Custodian service (“DWAC”), registered in
the name of the Investor. This Offering will not clear directly through an underwriter, placement agent or similar broker. Consequently,
the Investor must instruct their individual broker how to settle the transaction.

 

4.
The completion of the purchase and sale of the Shares shall occur at the closing (the “Closing”) which
shall occur on the Trading Day (as defined below) on which all conditions precedent to (i) the Investor’s obligation to
pay the aggregate purchase price for the Investor’s Shares (the “Subscription Amount”) and (ii) the Company’s
obligations to deliver the Investor’s Shares, in each case, have been satisfied or waived, but in no event later than January
26, 2021 (the “Closing Date”). On the Closing Date, (a) the Company shall cause its transfer agent to deliver
on an expedited basis via DWAC the Investor’s Shares and (b) the Subscription Amount will be delivered by or on behalf of
the Investor to the Company by wire transfer pursuant to the Company’s wire instructions delivered to the Investor on Company
letterhead prior to the Closing Date. In the event that the Company is unable to fulfill its obligations hereunder at Closing
by January 29, 2021, Investor shall have the right, but not the obligation, to terminate this Agreement and the Subscription hereunder.
For purposes of this Agreement, “Trading Day” means any day on which the Common Stock is traded on the principal
securities exchange or trading market on which the Common Stock is then traded (the “Exchange”); provided that
“Trading Day” shall not include any day on which the Common Stock is scheduled to trade on such exchange or market
for less than 4.5 hours or any day that the Common Stock is suspended from trading during the final hour of trading on such Exchange
(or if such Exchange does not designate in advance the closing time of trading on such Exchange, then during the hour ending at
4:00 p.m., New York time).

 

    	1

     

    

 

5.
The Registration Statement filed by the Company with the Commission contains a prospectus (the “Base Prospectus”)
and the Company will promptly file with the Commission a final prospectus supplement (the “Prospectus Supplement”
and collectively with the Base Prospectus, the “Prospectus”) with respect to the Registration Statement in
material conformity with the Securities Act, including Rule 424(b) thereunder. The Investor hereby consents to delivery of the
Prospectus in accordance with Rule 172 under the Securities Act.

 

6.
The obligations of the Company to issue and sell the Shares to the Investor shall be subject to: (i) the receipt by the Company
of the Subscription Amount and (ii) the accuracy of the representations and warranties made by the Investor and the fulfillment
of those undertakings of the Investor to be fulfilled prior to the Closing Date.

 

7.
Except as set forth in the SEC Reports (as defined below), the Company hereby makes the following representations, warranties
and covenants to the Investor:

 

(a)
The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
by this Agreement and the Other Investors’ Agreements and otherwise to carry out its obligations hereunder. The execution
and delivery of this Agreement by the Company and the consummation by it of the transactions contemplated hereunder have been
duly authorized by all necessary action on the part of the Company. This Agreement has been duly executed by the Company and,
when delivered in accordance with the terms hereof, will constitute the valid and binding obligation of the Company enforceable
against the Company in accordance with its terms, except as may be limited by any bankruptcy, insolvency, reorganization, moratorium,
fraudulent conveyance or other similar laws affecting the enforcement of creditors’ rights generally or by general principles
of equity.

 

(b)
The Shares are duly authorized and, when issued and paid for in accordance with this Agreement and the Other Investors’
Agreements, will be duly and validly issued, fully paid and nonassessable, free and clear of all liens imposed by the Company.
The Company has reserved from its duly authorized capital stock the maximum number of shares of Common Stock issuable pursuant
to this Agreement. The Company has prepared and filed the Registration Statement in material conformity with the requirements
of the Securities Act, which became effective on June 18, 2019 (the “Effective Date”), and such amendments
and supplements thereto as may have been required to the date of this Agreement. The Registration Statement is effective under
the Securities Act and no stop order preventing or suspending the effectiveness of the Registration Statement or suspending or
preventing the use of the Prospectus has been issued by the Commission and no proceedings for that purpose have been instituted
or, to the knowledge of the Company, are threatened by the Commission. The Company, if required by the rules and regulations of
the Commission, shall file the Prospectus Supplement with the Commission pursuant to Rule 424(b). At the time the Registration
Statement and any amendments thereto became effective, at the date of this Agreement and as of the Closing Date, the Registration
Statement and any amendments thereto conformed and will conform in all material respects to the requirements of the Securities
Act and did not and will not contain any untrue statement of a material fact or omit to state any material fact required to be
stated therein or necessary to make the statements therein not misleading; and the Prospectus and any amendments or supplements
thereto, at time the Prospectus or any amendment or supplement thereto was issued and as of the Closing Date, conformed and will
conform in all material respects to the requirements of the Securities Act and did not and will not contain an untrue statement
of a material fact or omit to state a material fact necessary in order to make the statements therein, in light of the circumstances
under which they were made, not misleading.

 

    	2

     

    

 

(c)
Other than pursuant to the Company’s Equity Distribution Agreement with Piper Sandler & Co., the Company has not
issued any capital stock since its most recently filed periodic report under the Exchange Act, other than pursuant to the exercise
of employee stock options under the Company’s stock option plans, the issuance of shares of Common Stock to employees pursuant
to the Company’s employee stock purchase plans and pursuant to the conversion and/or exercise of any securities convertible
into, exercisable or exchangeable for, or otherwise representing the right to acquire shares of Common Stock (each, a “Common
Stock Equivalent”) outstanding as of the date of the most recently filed SEC Report (as defined below). No Person has
any right of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions
contemplated by this Agreement. Except as otherwise disclosed in the SEC Reports (as defined below) or as a result of the purchase
and sale of the Shares, there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any
character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or
giving any Person any right to subscribe for or acquire, any shares of Common Stock, or contracts, commitments, understandings
or arrangements by which the Company or any of its consolidated subsidiaries (each a “Subsidiary”) is or may
become bound to issue additional shares of Common Stock or Common Stock Equivalents. The issuance and sale of the Shares will
not obligate the Company to issue shares of Common Stock or other securities to any person (other than to investors in this Offering)
and will not result in a right of any holder of Company securities to adjust the exercise, conversion, exchange or reset price
under any of such securities. All of the outstanding shares of capital stock of the Company are duly authorized, validly issued,
fully paid and nonassessable, have been issued in material compliance with all federal and state securities laws, and none of
such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities.
No further approval or authorization of any stockholder or the Board of Directors is required for the issuance and sale of the
Shares. Except as otherwise disclosed in the SEC Reports, there are no stockholders’ agreements, voting agreements or other
similar agreements with respect to the Company’s capital stock to which the Company is a party or, to the knowledge of the
Company, between or among any of the Company’s stockholders.

 

(d)
Since the date of the latest audited financial statements included within any report or definitive proxy or information statements
filed by the Company with the Commission pursuant to Sections 13(a), 13(c), 14, 15(d) or any other provision of or under the Exchange
Act (the “SEC Reports”), except as specifically disclosed in a subsequent SEC Report filed prior to the date
hereof, (i) there has been no event, occurrence or development that has had or that could reasonably be expected to result in
a material adverse effect, or any development that would reasonably be expected to result in a material adverse change, in the
condition, financial or otherwise, or in the results of operations, business, operations or prospects, whether or not arising
from transactions in the ordinary course of business, of the Company and its Subsidiaries, considered as one entity (any such
effect is called a “Material Adverse Effect”), (ii) the Company has not incurred any liabilities (contingent
or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past
practice and (B) liabilities not required to be reflected in the Company’s financial statements pursuant to United States
generally accepted accounting principles (“GAAP”) or disclosed in filings made with the Commission, (iii) the
Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend or distribution of cash
or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital
stock and (v) the Company has not issued any equity securities to any officer, director or affiliate, except pursuant to existing
Company stock option plans. The Company does not have pending before the Commission any request for confidential treatment of
information. Except for the issuance of the Shares contemplated by this Agreement and the Other Investors’ Agreements or
as set forth in the SEC Reports, no event, liability, fact, circumstance, occurrence or development has occurred or exists or
is reasonably expected to occur or exist with respect to the Company or its Subsidiaries or their respective businesses, prospects,
properties, operations, assets or financial condition that would be required to be disclosed by the Company under applicable securities
laws at the time this representation is made or deemed made that has not been publicly disclosed at least 1 Trading Day prior
to the date that this representation is made.

 

(e)
The Company shall (i) by the Disclosure Time (as defined below), issue a press release disclosing the material terms of the
transactions contemplated hereby and (ii) make such other filings and notices in the manner and time required by the Commission
with respect to the transactions contemplated hereby. The Company shall not identify the Investor by name in any press release
or public filing, or otherwise publicly disclose the Investor’s name, without the Investor’s prior written consent,
unless required by law or the rules and regulations of any self-regulatory organization or exchange to which the Company or its
securities are subject. For the purposes of this Agreement, “Disclosure Time” means, (i) if this Agreement
is signed on a day that is not a Trading Day or after 9:00 a.m. (New York City time) and before midnight (New York City time)
on any Trading Day, 9:01 a.m. (New York City time) on the Trading Day immediately following the date hereof, and (ii) if this
Agreement is signed between midnight (New York City time) and 9:00 a.m. (New York City time) on any Trading Day, no later than
9:01 a.m. (New York City time) on the date hereof.

 

    	3

     

    

 

(f)
The making, execution and performance of this Agreement by the Company and the consummation of the transactions contemplated
herein will not conflict with or result in a breach or violation of any of the terms and provisions of, or constitute a default
under, (i) the charter, bylaws or other organizational documents of the Company, as applicable, (ii) any law, order, rule, regulation,
writ, injunction, judgment or decree of any court, administrative agency, regulatory body, government or governmental agency or
body, domestic or foreign, having jurisdiction over the Company or its properties (including federal and state securities laws
and regulations and the rules and regulations of the NYSE American or other applicable Exchange) or (iii) conflict with, or constitute
a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights
of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the Company or any
of its Subsidiaries is a party, except for any conflict, breach, violation or default which is not reasonably likely to have a
material adverse effect on the Company, its Subsidiaries or any property or asset of the Company or any of its Subsidiaries or
the Company’s performance of its obligations hereunder or the consummation of the transactions contemplated hereby.

 

(g)
The Company is not required to obtain any consent, authorization or order of, or make any filing or registration with, any
court, governmental agency or any regulatory or self-regulatory agency or any other Person in order for it to execute, deliver
or perform any of its obligations hereunder in accordance with the terms hereof, other than (i) as may be required under the Securities
Act, (ii) any necessary qualification of the Shares under the securities or blue sky laws of the various jurisdictions in which
the Shares are being offered and (iii) under the rules and regulations of the Financial Industry Regulatory Authority (“FINRA”)
or the NYSE American. All consents, authorizations, orders, filings and registrations which the Company is required to obtain
pursuant to the preceding sentence will be obtained or effected on or prior to the Closing Date, and the Company and its Subsidiaries
are unaware of any facts or circumstances which might prevent the Company from obtaining or effecting any of the registration,
application or filings pursuant to the preceding sentence.

 

(h)
The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly, any action designed
to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale
or resale of any of the Shares, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases of, any of the
Shares, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities
of the Company.

 

8.
The Investor hereby makes the following representations, warranties and covenants to the Company:

 

(a)
The Investor represents that (i) it has received or had full access to the Base Prospectus, as well as the Company’s
periodic reports and other information incorporated by reference therein, prior to or in connection with its receipt of this Agreement,
(ii) it is knowledgeable, sophisticated and experienced in making, and is qualified to make, decisions with respect to investments
in securities representing an investment decision like that involved in the purchase of the Shares, and (iii) it does not have
any agreement or understanding, directly or indirectly, with any person or entity to distribute any of the Shares.

 

(b)
The Investor has the requisite power and authority to enter into this Agreement and to consummate the transactions contemplated
hereby. The execution and delivery of this Agreement by the Investor and the consummation by it of the transactions contemplated
hereunder have been duly authorized by all necessary action on the part of the Investor. This Agreement has been executed by the
Investor and, when delivered in accordance with the terms hereof, will constitute a valid and binding obligation of the Investor
enforceable against the Investor in accordance with its terms, except as enforceability may be limited by applicable bankruptcy,
insolvency, reorganization, moratorium or similar laws affecting creditors’ and contracting parties’ rights generally
and except as enforceability may be subject to general principles of equity (regardless of whether such enforceability is considered
in a proceeding in equity or at law).

 

    	4

     

    

 

(c)
The Investor understands that nothing in this Agreement or any other materials presented to the Investor in connection with
the purchase and sale of the Shares constitutes legal, tax or investment advice. The Investor has consulted such legal, tax and
investment advisors as it, in its sole discretion, has deemed necessary or appropriate in connection with its purchase of the
Shares.

 

(d)
The making, execution and performance of this Agreement by the Investor and the consummation of the transactions contemplated
herein will not conflict with or result in a breach or violation of any of the terms and provisions of, or constitute a default
under, (i) the charter, bylaws or other organizational documents of such Investor, as applicable, or (ii) any law, order, rule,
regulation, writ, injunction, judgment or decree of any court, administrative agency, regulatory body, government or governmental
agency or body, domestic or foreign, having jurisdiction over such Investor or its properties, except for any conflict, breach,
violation or default which is not reasonably likely to have a material adverse effect on such Investor’s performance of
its obligations hereunder or the consummation of the transactions contemplated hereby.

 

(e)
The Investor is a party to a confidentiality agreement with the Company, pursuant to which it will maintain the confidentiality
of, and not use in any way (including not trading on the basis of) all information acquired in connection with the transactions
contemplated herein prior to the public disclosure of that information by the Company.

 

(f)
Neither the Investor nor any Person acting on behalf of, or pursuant to any understanding with or based upon any information
received from, the Investor has, directly or indirectly, engaged in any purchases or sales of the securities of the Company (including,
without limitation, any Short Sales involving the Company’s securities) since the time that the Investor first discussed
the transactions contemplated hereby with the Company. “Short Sales” include, without limitation, all “short
sales” as defined in Rule 200 promulgated under Regulation SHO under the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), whether or not against the box, and all types of direct and indirect stock pledges, forward
sale contracts, options, puts, calls, short sales, swaps, “put equivalent positions” (as defined in Rule 16a-1(h)
under the Exchange Act) and similar arrangements (including on a total return basis), and sales and other transactions through
non-U.S. broker dealers or foreign regulated brokers. The Investor covenants that neither it, nor any Person acting on behalf
of, or pursuant to any understanding with or based upon any information received from, will engage in any purchases or sales of
the securities of the Company (including Short Sales) prior to the time that the Company confirms to the Purchaser in writing
that all material nonpublic information has been publicly disclosed.

 

(g)
The Investor represents that, except as set forth below, (i) it has had no position, office or other material relationship
within the past three years with the Company or persons known to it to be affiliates of the Company, (ii) it is not a, and it
has no direct or indirect association with any, FINRA member or an Associated Person (as such term is defined under the FINRA
Membership and Registration Rules Section 1011) as of the date hereof, and (iii) neither it nor any group of investors (as identified
in a public filing made with the Commission) of which it is a member, acquired, or obtained the right to acquire, 20% or more
of the Common Stock (or securities convertible or exercisable for Common Stock) or the voting power of the Company on a post-transaction
basis. Exceptions:

 

Those
matters disclosed in regulatory filings by the Investor and its affiliates

(If
no exceptions, write “none.” If left blank, response will be deemed to be “none.”)

 

    	5

     

    

 

(h)
The Investor acknowledges that it has had the opportunity to review this Agreement (including all exhibits and schedules thereto)
and the SEC Reports and has been afforded (i) the opportunity to ask such questions as it has deemed necessary of representatives
of the Company and to receive answers from such representatives concerning the terms and conditions of the offering of the Shares
and the merits and risks of investing in the Shares; (ii) access to information about the Company and its financial condition,
results of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and
(iii) the opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable effort
or expense that is necessary to make an informed investment decision with respect to the investment.

 

9.
Except as expressly set forth in this Agreement to the contrary, each party shall pay the fees and expenses of its advisers,
counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation,
execution, delivery and performance of this Agreement.

 

10.
Notwithstanding any investigation made by any party to this Agreement, all covenants, agreements, representations and warranties
made by the Company and the Investor herein will survive the execution of this Agreement, the delivery to the Investor of the
Shares being purchased and the payment therefor.

 

11.
This Agreement may not be modified or amended except pursuant to an instrument in writing signed by the Company and the Investor.

 

12.
In case any provision contained in this Agreement should be invalid, illegal or unenforceable in any respect, the validity,
legality and enforceability of the remaining provisions contained herein will not in any way be affected or impaired thereby.

 

13.
This Agreement will be governed by, and construed in accordance with, the internal laws of the State of New York, without
giving effect to the principles of conflicts of law that would require the application of the laws of any other jurisdiction.

 

14.
This Agreement may be executed in counterparts, each of which will constitute an original, but all of which, when taken together,
will constitute but one instrument, and will become effective when counterparts have been signed by each party hereto and delivered
to the other party, and such counterparts may be delivered electronically.

 

15.
This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and
is not for the benefit of, nor may any provision hereof be enforced by, any other Person.

 

16.
The Investor acknowledges and agrees that such Investor’s receipt of the Company’s counterpart to this Agreement
shall constitute written confirmation of the Company’s sale of Shares to such Investor.

 

[SIGNATURE
PAGES FOLLOW]

 

    	6

     

    

 

INVESTOR
SIGNATURE PAGE

 

Number
of Shares: 730,140

 

Purchase
Price Per Share: $3.424

 

Aggregate
Purchase Price: $2,499,999.36

 

Please
confirm that the foregoing correctly sets forth the agreement between us by signing in the space provided below for that purpose.

 

Dated
as of January 20, 2021

 

	INVESTOR	 
	 	 	 
	By:	/s/
    Efrem Kamen	 
	Print
    Name:	Eferm
    Kamen	 
	Title:	Managing
    Member of Pura Vida Investments, LLC in its capacity as sub-adviser to Investor

Name
in which Securities are to be registered: Walleye Opportunities Master Fund Ltd

Mailing
Address: c/o Pura Vida Investments, LLC, 150 East 52nd Street, Suite 32001, New York, NY, 10022

 

Facsimile
Number: c/o Pura Vida Investments:

 

Email
Address:

 

Taxpayer
Identification Number:

 

Manner
of Settlement of the Shares: DWAC (The Shares will be sent from the Company’s transfer agent, American Stock Transfer &
Trust Company, by DWAC to your prime broker. You must contact your prime broker and ask them to initiate the DWAC
or you will not receive the Shares. The Shares will only be released after the Company’s receipt of the funds.)

 

	Name
                                         of DTC Participant (broker-dealer at which the account or accounts to be credited with
                                         the Shares are maintained)
	 	 

        Please
        see the attached instructions

	 	 	 
	DTC
                                         Participant Number
	 	__________________________
	 	 	 
	Name
                                         of Account at DTC Participant being credited with the Shares
	 	 

         __________________________

	 	 	 
	Account
                                         Number at DTC Participant being credited with the Shares
	 	 

        __________________________ 

 

    	7

     

    

 

Agreed
and Accepted this 20th day of January, 2021:

 

	OncoCyte
    Corporation	 
	 	 	 
	By:	/s/
    Mitch Levine      	 
	Name:	Mitch
    Levine	 
	Title:	CFO	 

 

Sales
of the Shares purchased hereunder were made pursuant to a registration statement or in a transaction in which a final prospectus
would have been required to have been delivered in the absence of Rule 172 promulgated under the Securities Act.

 

    	8

     

    

 

SUBSCRIPTION
AGREEMENT

 

OncoCyte
Corporation

15
Cushing

Irvine,
CA 92618

 

Ladies
and Gentlemen:

 

The
undersigned (the “Investor”) hereby confirms and agrees with you as follows:

 

1.
This Subscription Agreement (this “Agreement”) is made as of the date set forth below between OncoCyte
Corporation, a California corporation (the “Company”), and the Investor.

 

2.
The Company is offering to sell and issue up to $25 million of shares, in the aggregate, (the “Shares”)
of the Company’s common stock, no par value per share (the “Common Stock” and such offering, the “Offering”)
at a per Share purchase price of $3.424 (subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations
and other similar transactions of the Common Stock that occur after the date of this Agreement). The Shares being offered have
been registered under the Securities Act of 1933, as amended (the “Securities Act”), pursuant to the Company’s
Registration Statement on Form S-3 (No. 333-231980), including all amendments thereto, the exhibits and any schedules thereto,
the documents otherwise deemed to be a part thereof or included therein by the rules and regulations (the “Rules and
Regulations”) of the U.S. Securities and Exchange Commission (the “Commission”) and any registration
statement relating to the Offering and filed pursuant to Rule 462(b) under the Rules and Regulations (collectively, the “Registration
Statement”). The Investor acknowledges that the Company intends to enter into subscription agreements in substantially
the same form as this Agreement, on the same terms and conditions and prices as hereunder (the “Other Investors’
Agreements”), with certain other accredited investors.

 

3.
As of the Closing (as defined below), and subject to the terms and conditions hereof, the Company and the Investor agree that
the Investor will purchase from the Company and the Company will issue and sell to the Investor such number of Shares (the “Subscription”
and such Shares, the “Investor’s Shares”) as is set forth on the signature page hereto (the “Signature
Page”). The Investor acknowledges that the Offering is being conducted on a best-efforts basis and there is no minimum
offering amount. On the Closing Date, (as defined below), the Investor’s Shares will be delivered on an expedited basis
via The Depository Trust Company’s Deposit and Withdrawal at Custodian service (“DWAC”), registered in
the name of the Investor. This Offering will not clear directly through an underwriter, placement agent or similar broker. Consequently,
the Investor must instruct their individual broker how to settle the transaction.

 

4.
The completion of the purchase and sale of the Shares shall occur at the closing (the “Closing”) which
shall occur on the Trading Day (as defined below) on which all conditions precedent to (i) the Investor’s obligation to
pay the aggregate purchase price for the Investor’s Shares (the “Subscription Amount”) and (ii) the Company’s
obligations to deliver the Investor’s Shares, in each case, have been satisfied or waived, but in no event later than January
26, 2021 (the “Closing Date”). On the Closing Date, (a) the Company shall cause its transfer agent to deliver
on an expedited basis via DWAC the Investor’s Shares and (b) the Subscription Amount will be delivered by or on behalf of
the Investor to the Company by wire transfer pursuant to the Company’s wire instructions delivered to the Investor on Company
letterhead prior to the Closing Date. In the event that the Company is unable to fulfill its obligations hereunder at Closing
by January 29, 2021, Investor shall have the right, but not the obligation, to terminate this Agreement and the Subscription hereunder.
For purposes of this Agreement, “Trading Day” means any day on which the Common Stock is traded on the principal
securities exchange or trading market on which the Common Stock is then traded (the “Exchange”); provided that
“Trading Day” shall not include any day on which the Common Stock is scheduled to trade on such exchange or market
for less than 4.5 hours or any day that the Common Stock is suspended from trading during the final hour of trading on such Exchange
(or if such Exchange does not designate in advance the closing time of trading on such Exchange, then during the hour ending at
4:00 p.m., New York time).

 

    	1

     

    

 

5.
The Registration Statement filed by the Company with the Commission contains a prospectus (the “Base Prospectus”)
and the Company will promptly file with the Commission a final prospectus supplement (the “Prospectus Supplement”
and collectively with the Base Prospectus, the “Prospectus”) with respect to the Registration Statement in
material conformity with the Securities Act, including Rule 424(b) thereunder. The Investor hereby consents to delivery of the
Prospectus in accordance with Rule 172 under the Securities Act.

 

6.
The obligations of the Company to issue and sell the Shares to the Investor shall be subject to: (i) the receipt by the Company
of the Subscription Amount and (ii) the accuracy of the representations and warranties made by the Investor and the fulfillment
of those undertakings of the Investor to be fulfilled prior to the Closing Date.

 

7.
Except as set forth in the SEC Reports (as defined below), the Company hereby makes the following representations, warranties
and covenants to the Investor:

 

(a)
The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
by this Agreement and the Other Investors’ Agreements and otherwise to carry out its obligations hereunder. The execution
and delivery of this Agreement by the Company and the consummation by it of the transactions contemplated hereunder have been
duly authorized by all necessary action on the part of the Company. This Agreement has been duly executed by the Company and,
when delivered in accordance with the terms hereof, will constitute the valid and binding obligation of the Company enforceable
against the Company in accordance with its terms, except as may be limited by any bankruptcy, insolvency, reorganization, moratorium,
fraudulent conveyance or other similar laws affecting the enforcement of creditors’ rights generally or by general principles
of equity.

 

(b)
The Shares are duly authorized and, when issued and paid for in accordance with this Agreement and the Other Investors’
Agreements, will be duly and validly issued, fully paid and nonassessable, free and clear of all liens imposed by the Company.
The Company has reserved from its duly authorized capital stock the maximum number of shares of Common Stock issuable pursuant
to this Agreement. The Company has prepared and filed the Registration Statement in material conformity with the requirements
of the Securities Act, which became effective on June 18, 2019 (the “Effective Date”), and such amendments
and supplements thereto as may have been required to the date of this Agreement. The Registration Statement is effective under
the Securities Act and no stop order preventing or suspending the effectiveness of the Registration Statement or suspending or
preventing the use of the Prospectus has been issued by the Commission and no proceedings for that purpose have been instituted
or, to the knowledge of the Company, are threatened by the Commission. The Company, if required by the rules and regulations of
the Commission, shall file the Prospectus Supplement with the Commission pursuant to Rule 424(b). At the time the Registration
Statement and any amendments thereto became effective, at the date of this Agreement and as of the Closing Date, the Registration
Statement and any amendments thereto conformed and will conform in all material respects to the requirements of the Securities
Act and did not and will not contain any untrue statement of a material fact or omit to state any material fact required to be
stated therein or necessary to make the statements therein not misleading; and the Prospectus and any amendments or supplements
thereto, at time the Prospectus or any amendment or supplement thereto was issued and as of the Closing Date, conformed and will
conform in all material respects to the requirements of the Securities Act and did not and will not contain an untrue statement
of a material fact or omit to state a material fact necessary in order to make the statements therein, in light of the circumstances
under which they were made, not misleading.

 

    	2

     

    

 

(c)
Other than pursuant to the Company’s Equity Distribution Agreement with Piper Sandler & Co., the Company has not
issued any capital stock since its most recently filed periodic report under the Exchange Act, other than pursuant to the exercise
of employee stock options under the Company’s stock option plans, the issuance of shares of Common Stock to employees pursuant
to the Company’s employee stock purchase plans and pursuant to the conversion and/or exercise of any securities convertible
into, exercisable or exchangeable for, or otherwise representing the right to acquire shares of Common Stock (each, a “Common
Stock Equivalent”) outstanding as of the date of the most recently filed SEC Report (as defined below). No Person has
any right of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions
contemplated by this Agreement. Except as otherwise disclosed in the SEC Reports (as defined below) or as a result of the purchase
and sale of the Shares, there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any
character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or
giving any Person any right to subscribe for or acquire, any shares of Common Stock, or contracts, commitments, understandings
or arrangements by which the Company or any of its consolidated subsidiaries (each a “Subsidiary”) is or may
become bound to issue additional shares of Common Stock or Common Stock Equivalents. The issuance and sale of the Shares will
not obligate the Company to issue shares of Common Stock or other securities to any person (other than to investors in this Offering)
and will not result in a right of any holder of Company securities to adjust the exercise, conversion, exchange or reset price
under any of such securities. All of the outstanding shares of capital stock of the Company are duly authorized, validly issued,
fully paid and nonassessable, have been issued in material compliance with all federal and state securities laws, and none of
such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities.
No further approval or authorization of any stockholder or the Board of Directors is required for the issuance and sale of the
Shares. Except as otherwise disclosed in the SEC Reports, there are no stockholders’ agreements, voting agreements or other
similar agreements with respect to the Company’s capital stock to which the Company is a party or, to the knowledge of the
Company, between or among any of the Company’s stockholders.

 

(d)
Since the date of the latest audited financial statements included within any report or definitive proxy or information statements
filed by the Company with the Commission pursuant to Sections 13(a), 13(c), 14, 15(d) or any other provision of or under the Exchange
Act (the “SEC Reports”), except as specifically disclosed in a subsequent SEC Report filed prior to the date
hereof, (i) there has been no event, occurrence or development that has had or that could reasonably be expected to result in
a material adverse effect, or any development that would reasonably be expected to result in a material adverse change, in the
condition, financial or otherwise, or in the results of operations, business, operations or prospects, whether or not arising
from transactions in the ordinary course of business, of the Company and its Subsidiaries, considered as one entity (any such
effect is called a “Material Adverse Effect”), (ii) the Company has not incurred any liabilities (contingent
or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past
practice and (B) liabilities not required to be reflected in the Company’s financial statements pursuant to United States
generally accepted accounting principles (“GAAP”) or disclosed in filings made with the Commission, (iii) the
Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend or distribution of cash
or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital
stock and (v) the Company has not issued any equity securities to any officer, director or affiliate, except pursuant to existing
Company stock option plans. The Company does not have pending before the Commission any request for confidential treatment of
information. Except for the issuance of the Shares contemplated by this Agreement and the Other Investors’ Agreements or
as set forth in the SEC Reports, no event, liability, fact, circumstance, occurrence or development has occurred or exists or
is reasonably expected to occur or exist with respect to the Company or its Subsidiaries or their respective businesses, prospects,
properties, operations, assets or financial condition that would be required to be disclosed by the Company under applicable securities
laws at the time this representation is made or deemed made that has not been publicly disclosed at least 1 Trading Day prior
to the date that this representation is made.

 

(e)
The Company shall (i) by the Disclosure Time (as defined below), issue a press release disclosing the material terms of the
transactions contemplated hereby and (ii) make such other filings and notices in the manner and time required by the Commission
with respect to the transactions contemplated hereby. The Company shall not identify the Investor by name in any press release
or public filing, or otherwise publicly disclose the Investor’s name, without the Investor’s prior written consent,
unless required by law or the rules and regulations of any self-regulatory organization or exchange to which the Company or its
securities are subject. For the purposes of this Agreement, “Disclosure Time” means, (i) if this Agreement
is signed on a day that is not a Trading Day or after 9:00 a.m. (New York City time) and before midnight (New York City time)
on any Trading Day, 9:01 a.m. (New York City time) on the Trading Day immediately following the date hereof, and (ii) if this
Agreement is signed between midnight (New York City time) and 9:00 a.m. (New York City time) on any Trading Day, no later than
9:01 a.m. (New York City time) on the date hereof.

 

    	3

     

    

 

(f)
The making, execution and performance of this Agreement by the Company and the consummation of the transactions contemplated
herein will not conflict with or result in a breach or violation of any of the terms and provisions of, or constitute a default
under, (i) the charter, bylaws or other organizational documents of the Company, as applicable, (ii) any law, order, rule, regulation,
writ, injunction, judgment or decree of any court, administrative agency, regulatory body, government or governmental agency or
body, domestic or foreign, having jurisdiction over the Company or its properties (including federal and state securities laws
and regulations and the rules and regulations of the NYSE American or other applicable Exchange) or (iii) conflict with, or constitute
a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights
of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the Company or any
of its Subsidiaries is a party, except for any conflict, breach, violation or default which is not reasonably likely to have a
material adverse effect on the Company, its Subsidiaries or any property or asset of the Company or any of its Subsidiaries or
the Company’s performance of its obligations hereunder or the consummation of the transactions contemplated hereby.

 

(g)
The Company is not required to obtain any consent, authorization or order of, or make any filing or registration with, any
court, governmental agency or any regulatory or self-regulatory agency or any other Person in order for it to execute, deliver
or perform any of its obligations hereunder in accordance with the terms hereof, other than (i) as may be required under the Securities
Act, (ii) any necessary qualification of the Shares under the securities or blue sky laws of the various jurisdictions in which
the Shares are being offered and (iii) under the rules and regulations of the Financial Industry Regulatory Authority (“FINRA”)
or the NYSE American. All consents, authorizations, orders, filings and registrations which the Company is required to obtain
pursuant to the preceding sentence will be obtained or effected on or prior to the Closing Date, and the Company and its Subsidiaries
are unaware of any facts or circumstances which might prevent the Company from obtaining or effecting any of the registration,
application or filings pursuant to the preceding sentence.

 

(h)
The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly, any action designed
to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale
or resale of any of the Shares, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases of, any of the
Shares, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities
of the Company.

 

8.
The Investor hereby makes the following representations, warranties and covenants to the Company:

 

(a)
The Investor represents that (i) it has received or had full access to the Base Prospectus, as well as the Company’s
periodic reports and other information incorporated by reference therein, prior to or in connection with its receipt of this Agreement,
(ii) it is knowledgeable, sophisticated and experienced in making, and is qualified to make, decisions with respect to investments
in securities representing an investment decision like that involved in the purchase of the Shares, and (iii) it does not have
any agreement or understanding, directly or indirectly, with any person or entity to distribute any of the Shares.

 

(b)
The Investor has the requisite power and authority to enter into this Agreement and to consummate the transactions contemplated
hereby. The execution and delivery of this Agreement by the Investor and the consummation by it of the transactions contemplated
hereunder have been duly authorized by all necessary action on the part of the Investor. This Agreement has been executed by the
Investor and, when delivered in accordance with the terms hereof, will constitute a valid and binding obligation of the Investor
enforceable against the Investor in accordance with its terms, except as enforceability may be limited by applicable bankruptcy,
insolvency, reorganization, moratorium or similar laws affecting creditors’ and contracting parties’ rights generally
and except as enforceability may be subject to general principles of equity (regardless of whether such enforceability is considered
in a proceeding in equity or at law).

 

    	4

     

    

 

(c)
The Investor understands that nothing in this Agreement or any other materials presented to the Investor in connection with
the purchase and sale of the Shares constitutes legal, tax or investment advice. The Investor has consulted such legal, tax and
investment advisors as it, in its sole discretion, has deemed necessary or appropriate in connection with its purchase of the
Shares.

 

(d)
The making, execution and performance of this Agreement by the Investor and the consummation of the transactions contemplated
herein will not conflict with or result in a breach or violation of any of the terms and provisions of, or constitute a default
under, (i) the charter, bylaws or other organizational documents of such Investor, as applicable, or (ii) any law, order, rule,
regulation, writ, injunction, judgment or decree of any court, administrative agency, regulatory body, government or governmental
agency or body, domestic or foreign, having jurisdiction over such Investor or its properties, except for any conflict, breach,
violation or default which is not reasonably likely to have a material adverse effect on such Investor’s performance of
its obligations hereunder or the consummation of the transactions contemplated hereby.

 

(e)
The Investor is a party to a confidentiality agreement with the Company, pursuant to which it will maintain the confidentiality
of, and not use in any way (including not trading on the basis of) all information acquired in connection with the transactions
contemplated herein prior to the public disclosure of that information by the Company.

 

(f)
Neither the Investor nor any Person acting on behalf of, or pursuant to any understanding with or based upon any information
received from, the Investor has, directly or indirectly, engaged in any purchases or sales of the securities of the Company (including,
without limitation, any Short Sales involving the Company’s securities) since the time that the Investor first discussed
the transactions contemplated hereby with the Company. “Short Sales” include, without limitation, all “short
sales” as defined in Rule 200 promulgated under Regulation SHO under the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), whether or not against the box, and all types of direct and indirect stock pledges, forward
sale contracts, options, puts, calls, short sales, swaps, “put equivalent positions” (as defined in Rule 16a-1(h)
under the Exchange Act) and similar arrangements (including on a total return basis), and sales and other transactions through
non-U.S. broker dealers or foreign regulated brokers. The Investor covenants that neither it, nor any Person acting on behalf
of, or pursuant to any understanding with or based upon any information received from, will engage in any purchases or sales of
the securities of the Company (including Short Sales) prior to the time that the Company confirms to the Purchaser in writing
that all material nonpublic information has been publicly disclosed.

 

(g)
The Investor represents that, except as set forth below, (i) it has had no position, office or other material relationship
within the past three years with the Company or persons known to it to be affiliates of the Company, (ii) it is not a, and it
has no direct or indirect association with any, FINRA member or an Associated Person (as such term is defined under the FINRA
Membership and Registration Rules Section 1011) as of the date hereof, and (iii) neither it nor any group of investors (as identified
in a public filing made with the Commission) of which it is a member, acquired, or obtained the right to acquire, 20% or more
of the Common Stock (or securities convertible or exercisable for Common Stock) or the voting power of the Company on a post-transaction
basis. Exceptions:

 

Those
matters disclosed in regulatory filings by the Investor and its affiliates

(If
no exceptions, write “none.” If left blank, response will be deemed to be “none.”)

 

    	5

     

    

 

(h)
The Investor acknowledges that it has had the opportunity to review this Agreement (including all exhibits and schedules thereto)
and the SEC Reports and has been afforded (i) the opportunity to ask such questions as it has deemed necessary of representatives
of the Company and to receive answers from such representatives concerning the terms and conditions of the offering of the Shares
and the merits and risks of investing in the Shares; (ii) access to information about the Company and its financial condition,
results of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and
(iii) the opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable effort
or expense that is necessary to make an informed investment decision with respect to the investment.

 

9.
Except as expressly set forth in this Agreement to the contrary, each party shall pay the fees and expenses of its advisers,
counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation,
execution, delivery and performance of this Agreement.

 

10.
Notwithstanding any investigation made by any party to this Agreement, all covenants, agreements, representations and warranties
made by the Company and the Investor herein will survive the execution of this Agreement, the delivery to the Investor of the
Shares being purchased and the payment therefor.

 

11.
This Agreement may not be modified or amended except pursuant to an instrument in writing signed by the Company and the Investor.

 

12.
In case any provision contained in this Agreement should be invalid, illegal or unenforceable in any respect, the validity,
legality and enforceability of the remaining provisions contained herein will not in any way be affected or impaired thereby.

 

13.
This Agreement will be governed by, and construed in accordance with, the internal laws of the State of New York, without
giving effect to the principles of conflicts of law that would require the application of the laws of any other jurisdiction.

 

14.
This Agreement may be executed in counterparts, each of which will constitute an original, but all of which, when taken together,
will constitute but one instrument, and will become effective when counterparts have been signed by each party hereto and delivered
to the other party, and such counterparts may be delivered electronically.

 

15.
This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and
is not for the benefit of, nor may any provision hereof be enforced by, any other Person.

 

16.
The Investor acknowledges and agrees that such Investor’s receipt of the Company’s counterpart to this Agreement
shall constitute written confirmation of the Company’s sale of Shares to such Investor.

 

[SIGNATURE
PAGES FOLLOW]

 

    	6

     

    

 

INVESTOR
SIGNATURE PAGE

 

Number
of Shares: 730,140

 

Purchase
Price Per Share: $3.424

 

Aggregate
Purchase Price: $2,499,999.36

 

Please
confirm that the foregoing correctly sets forth the agreement between us by signing in the space provided below for that purpose.

 

Dated
as of January 20, 2021

 

	INVESTOR	 
	 	 	 
	By:	/s/
    Efrem Kamen	 
	Print
    Name:	Eferm
    Kamen	 
	Title:	Managing
    Member of Pura Vida Investments, LLC in its capacity as sub-adviser to Investor

Name
in which Securities are to be registered: Walleye Manager Opportunities LLC

Mailing
Address: c/o Pura Vida Investments, LLC, 150 East 52nd Street, Suite 32001, New York, NY, 10022

 

Facsimile
Number: c/o Pura Vida Investments:

Email
Address:

Taxpayer
Identification Number:

Manner
of Settlement of the Shares: DWAC (The Shares will be sent from the Company's transfer agent, American Stock Transfer & Trust
Company, by DWAC to your prime broker. You must contact your prime broker and ask them to initiate the DWAC or you
will not receive the Shares. The Shares will only be released after the Company’s receipt of the funds.)

 

	Name
                                         of DTC Participant (broker-dealer at which the account or accounts to be credited with
                                         the Shares are maintained)
	 	 

        Please
        see the attached instructions

	 	 	 
	DTC
                                         Participant Number
	 	__________________________
	 	 	 
	Name
                                         of Account at DTC Participant being credited with the Shares
	 	 

         __________________________

	 	 	 
	Account
                                         Number at DTC Participant being credited with the Shares
	 	 

        __________________________ 

 

    	7

     

    

 

Agreed
and Accepted this 20th day of January, 2021:

 

	OncoCyte
    Corporation	 
	 	 	 
	By:	/s/
    Mitch Levine      	 
	Name:	Mitch
    Levine	 
	Title:	CFO	 

 

Sales
of the Shares purchased hereunder were made pursuant to a registration statement or in a transaction in which a final prospectus
would have been required to have been delivered in the absence of Rule 172 promulgated under the Securities Act.

 

    	8

     

    

 

SUBSCRIPTION
AGREEMENT

 

OncoCyte
Corporation

15
Cushing

Irvine,
CA 92618

 

Ladies
and Gentlemen:

 

The
undersigned (the “Investor”) hereby confirms and agrees with you as follows:

 

1.
This Subscription Agreement (this “Agreement”) is made as of the date set forth below between OncoCyte
Corporation, a California corporation (the “Company”), and the Investor.

 

2.
The Company is offering to sell and issue up to $25 million of shares, in the aggregate, (the “Shares”)
of the Company’s common stock, no par value per share (the “Common Stock” and such offering, the “Offering”)
at a per Share purchase price of $3.424 (subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations
and other similar transactions of the Common Stock that occur after the date of this Agreement). The Shares being offered have
been registered under the Securities Act of 1933, as amended (the “Securities Act”), pursuant to the Company’s
Registration Statement on Form S-3 (No. 333-231980), including all amendments thereto, the exhibits and any schedules thereto,
the documents otherwise deemed to be a part thereof or included therein by the rules and regulations (the “Rules and
Regulations”) of the U.S. Securities and Exchange Commission (the “Commission”) and any registration
statement relating to the Offering and filed pursuant to Rule 462(b) under the Rules and Regulations (collectively, the “Registration
Statement”). The Investor acknowledges that the Company intends to enter into subscription agreements in substantially
the same form as this Agreement, on the same terms and conditions and prices as hereunder (the “Other Investors’
Agreements”), with certain other accredited investors.

 

3.
As of the Closing (as defined below), and subject to the terms and conditions hereof, the Company and the Investor agree that
the Investor will purchase from the Company and the Company will issue and sell to the Investor such number of Shares (the “Subscription”
and such Shares, the “Investor’s Shares”) as is set forth on the signature page hereto (the “Signature
Page”). The Investor acknowledges that the Offering is being conducted on a best-efforts basis and there is no minimum
offering amount. On the Closing Date, (as defined below), the Investor’s Shares will be delivered on an expedited basis
via The Depository Trust Company’s Deposit and Withdrawal at Custodian service (“DWAC”), registered in
the name of the Investor. This Offering will not clear directly through an underwriter, placement agent or similar broker. Consequently,
the Investor must instruct their individual broker how to settle the transaction.

 

4.
The completion of the purchase and sale of the Shares shall occur at the closing (the “Closing”) which
shall occur on the Trading Day (as defined below) on which all conditions precedent to (i) the Investor’s obligation to
pay the aggregate purchase price for the Investor’s Shares (the “Subscription Amount”) and (ii) the Company’s
obligations to deliver the Investor’s Shares, in each case, have been satisfied or waived, but in no event later than January
26, 2021 (the “Closing Date”). On the Closing Date, (a) the Company shall cause its transfer agent to deliver
on an expedited basis via DWAC the Investor’s Shares and (b) the Subscription Amount will be delivered by or on behalf of
the Investor to the Company by wire transfer pursuant to the Company’s wire instructions delivered to the Investor on Company
letterhead prior to the Closing Date. In the event that the Company is unable to fulfill its obligations hereunder at Closing
by January 29, 2021, Investor shall have the right, but not the obligation, to terminate this Agreement and the Subscription hereunder.
For purposes of this Agreement, “Trading Day” means any day on which the Common Stock is traded on the principal
securities exchange or trading market on which the Common Stock is then traded (the “Exchange”); provided that
“Trading Day” shall not include any day on which the Common Stock is scheduled to trade on such exchange or market
for less than 4.5 hours or any day that the Common Stock is suspended from trading during the final hour of trading on such Exchange
(or if such Exchange does not designate in advance the closing time of trading on such Exchange, then during the hour ending at
4:00 p.m., New York time).

 

    	1

     

    

 

5.
The Registration Statement filed by the Company with the Commission contains a prospectus (the “Base Prospectus”)
and the Company will promptly file with the Commission a final prospectus supplement (the “Prospectus Supplement”
and collectively with the Base Prospectus, the “Prospectus”) with respect to the Registration Statement in
material conformity with the Securities Act, including Rule 424(b) thereunder. The Investor hereby consents to delivery of the
Prospectus in accordance with Rule 172 under the Securities Act.

 

6.
The obligations of the Company to issue and sell the Shares to the Investor shall be subject to: (i) the receipt by the Company
of the Subscription Amount and (ii) the accuracy of the representations and warranties made by the Investor and the fulfillment
of those undertakings of the Investor to be fulfilled prior to the Closing Date.

 

7.
Except as set forth in the SEC Reports (as defined below), the Company hereby makes the following representations, warranties
and covenants to the Investor:

 

(a)
The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
by this Agreement and the Other Investors’ Agreements and otherwise to carry out its obligations hereunder. The execution
and delivery of this Agreement by the Company and the consummation by it of the transactions contemplated hereunder have been
duly authorized by all necessary action on the part of the Company. This Agreement has been duly executed by the Company and,
when delivered in accordance with the terms hereof, will constitute the valid and binding obligation of the Company enforceable
against the Company in accordance with its terms, except as may be limited by any bankruptcy, insolvency, reorganization, moratorium,
fraudulent conveyance or other similar laws affecting the enforcement of creditors’ rights generally or by general principles
of equity.

 

(b)
The Shares are duly authorized and, when issued and paid for in accordance with this Agreement and the Other Investors’
Agreements, will be duly and validly issued, fully paid and nonassessable, free and clear of all liens imposed by the Company.
The Company has reserved from its duly authorized capital stock the maximum number of shares of Common Stock issuable pursuant
to this Agreement. The Company has prepared and filed the Registration Statement in material conformity with the requirements
of the Securities Act, which became effective on June 18, 2019 (the “Effective Date”), and such amendments
and supplements thereto as may have been required to the date of this Agreement. The Registration Statement is effective under
the Securities Act and no stop order preventing or suspending the effectiveness of the Registration Statement or suspending or
preventing the use of the Prospectus has been issued by the Commission and no proceedings for that purpose have been instituted
or, to the knowledge of the Company, are threatened by the Commission. The Company, if required by the rules and regulations of
the Commission, shall file the Prospectus Supplement with the Commission pursuant to Rule 424(b). At the time the Registration
Statement and any amendments thereto became effective, at the date of this Agreement and as of the Closing Date, the Registration
Statement and any amendments thereto conformed and will conform in all material respects to the requirements of the Securities
Act and did not and will not contain any untrue statement of a material fact or omit to state any material fact required to be
stated therein or necessary to make the statements therein not misleading; and the Prospectus and any amendments or supplements
thereto, at time the Prospectus or any amendment or supplement thereto was issued and as of the Closing Date, conformed and will
conform in all material respects to the requirements of the Securities Act and did not and will not contain an untrue statement
of a material fact or omit to state a material fact necessary in order to make the statements therein, in light of the circumstances
under which they were made, not misleading.

 

    	2

     

    

 

(c)
Other than pursuant to the Company’s Equity Distribution Agreement with Piper Sandler & Co., the Company has not
issued any capital stock since its most recently filed periodic report under the Exchange Act, other than pursuant to the exercise
of employee stock options under the Company’s stock option plans, the issuance of shares of Common Stock to employees pursuant
to the Company’s employee stock purchase plans and pursuant to the conversion and/or exercise of any securities convertible
into, exercisable or exchangeable for, or otherwise representing the right to acquire shares of Common Stock (each, a “Common
Stock Equivalent”) outstanding as of the date of the most recently filed SEC Report (as defined below). No Person has
any right of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions
contemplated by this Agreement. Except as otherwise disclosed in the SEC Reports (as defined below) or as a result of the purchase
and sale of the Shares, there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any
character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or
giving any Person any right to subscribe for or acquire, any shares of Common Stock, or contracts, commitments, understandings
or arrangements by which the Company or any of its consolidated subsidiaries (each a “Subsidiary”) is or may
become bound to issue additional shares of Common Stock or Common Stock Equivalents. The issuance and sale of the Shares will
not obligate the Company to issue shares of Common Stock or other securities to any person (other than to investors in this Offering)
and will not result in a right of any holder of Company securities to adjust the exercise, conversion, exchange or reset price
under any of such securities. All of the outstanding shares of capital stock of the Company are duly authorized, validly issued,
fully paid and nonassessable, have been issued in material compliance with all federal and state securities laws, and none of
such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities.
No further approval or authorization of any stockholder or the Board of Directors is required for the issuance and sale of the
Shares. Except as otherwise disclosed in the SEC Reports, there are no stockholders’ agreements, voting agreements or other
similar agreements with respect to the Company’s capital stock to which the Company is a party or, to the knowledge of the
Company, between or among any of the Company’s stockholders.

 

(d)
Since the date of the latest audited financial statements included within any report or definitive proxy or information statements
filed by the Company with the Commission pursuant to Sections 13(a), 13(c), 14, 15(d) or any other provision of or under the Exchange
Act (the “SEC Reports”), except as specifically disclosed in a subsequent SEC Report filed prior to the date
hereof, (i) there has been no event, occurrence or development that has had or that could reasonably be expected to result in
a material adverse effect, or any development that would reasonably be expected to result in a material adverse change, in the
condition, financial or otherwise, or in the results of operations, business, operations or prospects, whether or not arising
from transactions in the ordinary course of business, of the Company and its Subsidiaries, considered as one entity (any such
effect is called a “Material Adverse Effect”), (ii) the Company has not incurred any liabilities (contingent
or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past
practice and (B) liabilities not required to be reflected in the Company’s financial statements pursuant to United States
generally accepted accounting principles (“GAAP”) or disclosed in filings made with the Commission, (iii) the
Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend or distribution of cash
or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital
stock and (v) the Company has not issued any equity securities to any officer, director or affiliate, except pursuant to existing
Company stock option plans. The Company does not have pending before the Commission any request for confidential treatment of
information. Except for the issuance of the Shares contemplated by this Agreement and the Other Investors’ Agreements or
as set forth in the SEC Reports, no event, liability, fact, circumstance, occurrence or development has occurred or exists or
is reasonably expected to occur or exist with respect to the Company or its Subsidiaries or their respective businesses, prospects,
properties, operations, assets or financial condition that would be required to be disclosed by the Company under applicable securities
laws at the time this representation is made or deemed made that has not been publicly disclosed at least 1 Trading Day prior
to the date that this representation is made.

 

(e)
The Company shall (i) by the Disclosure Time (as defined below), issue a press release disclosing the material terms of the
transactions contemplated hereby and (ii) make such other filings and notices in the manner and time required by the Commission
with respect to the transactions contemplated hereby. The Company shall not identify the Investor by name in any press release
or public filing, or otherwise publicly disclose the Investor’s name, without the Investor’s prior written consent,
unless required by law or the rules and regulations of any self-regulatory organization or exchange to which the Company or its
securities are subject. For the purposes of this Agreement, “Disclosure Time” means, (i) if this Agreement
is signed on a day that is not a Trading Day or after 9:00 a.m. (New York City time) and before midnight (New York City time)
on any Trading Day, 9:01 a.m. (New York City time) on the Trading Day immediately following the date hereof, and (ii) if this
Agreement is signed between midnight (New York City time) and 9:00 a.m. (New York City time) on any Trading Day, no later than
9:01 a.m. (New York City time) on the date hereof.

 

    	3

     

    

 

(f)
The making, execution and performance of this Agreement by the Company and the consummation of the transactions contemplated
herein will not conflict with or result in a breach or violation of any of the terms and provisions of, or constitute a default
under, (i) the charter, bylaws or other organizational documents of the Company, as applicable, (ii) any law, order, rule, regulation,
writ, injunction, judgment or decree of any court, administrative agency, regulatory body, government or governmental agency or
body, domestic or foreign, having jurisdiction over the Company or its properties (including federal and state securities laws
and regulations and the rules and regulations of the NYSE American or other applicable Exchange) or (iii) conflict with, or constitute
a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights
of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the Company or any
of its Subsidiaries is a party, except for any conflict, breach, violation or default which is not reasonably likely to have a
material adverse effect on the Company, its Subsidiaries or any property or asset of the Company or any of its Subsidiaries or
the Company’s performance of its obligations hereunder or the consummation of the transactions contemplated hereby.

 

(g)
The Company is not required to obtain any consent, authorization or order of, or make any filing or registration with, any
court, governmental agency or any regulatory or self-regulatory agency or any other Person in order for it to execute, deliver
or perform any of its obligations hereunder in accordance with the terms hereof, other than (i) as may be required under the Securities
Act, (ii) any necessary qualification of the Shares under the securities or blue sky laws of the various jurisdictions in which
the Shares are being offered and (iii) under the rules and regulations of the Financial Industry Regulatory Authority (“FINRA”)
or the NYSE American. All consents, authorizations, orders, filings and registrations which the Company is required to obtain
pursuant to the preceding sentence will be obtained or effected on or prior to the Closing Date, and the Company and its Subsidiaries
are unaware of any facts or circumstances which might prevent the Company from obtaining or effecting any of the registration,
application or filings pursuant to the preceding sentence.

 

(h)
The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly, any action designed
to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale
or resale of any of the Shares, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases of, any of the
Shares, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities
of the Company.

 

8.
The Investor hereby makes the following representations, warranties and covenants to the Company:

 

(a)
The Investor represents that (i) it has received or had full access to the Base Prospectus, as well as the Company’s
periodic reports and other information incorporated by reference therein, prior to or in connection with its receipt of this Agreement,
(ii) it is knowledgeable, sophisticated and experienced in making, and is qualified to make, decisions with respect to investments
in securities representing an investment decision like that involved in the purchase of the Shares, and (iii) it does not have
any agreement or understanding, directly or indirectly, with any person or entity to distribute any of the Shares.

 

(b)
The Investor has the requisite power and authority to enter into this Agreement and to consummate the transactions contemplated
hereby. The execution and delivery of this Agreement by the Investor and the consummation by it of the transactions contemplated
hereunder have been duly authorized by all necessary action on the part of the Investor. This Agreement has been executed by the
Investor and, when delivered in accordance with the terms hereof, will constitute a valid and binding obligation of the Investor
enforceable against the Investor in accordance with its terms, except as enforceability may be limited by applicable bankruptcy,
insolvency, reorganization, moratorium or similar laws affecting creditors’ and contracting parties’ rights generally
and except as enforceability may be subject to general principles of equity (regardless of whether such enforceability is considered
in a proceeding in equity or at law).

 

    	4

     

    

 

(c)
The Investor understands that nothing in this Agreement or any other materials presented to the Investor in connection with
the purchase and sale of the Shares constitutes legal, tax or investment advice. The Investor has consulted such legal, tax and
investment advisors as it, in its sole discretion, has deemed necessary or appropriate in connection with its purchase of the
Shares.

 

(d)
The making, execution and performance of this Agreement by the Investor and the consummation of the transactions contemplated
herein will not conflict with or result in a breach or violation of any of the terms and provisions of, or constitute a default
under, (i) the charter, bylaws or other organizational documents of such Investor, as applicable, or (ii) any law, order, rule,
regulation, writ, injunction, judgment or decree of any court, administrative agency, regulatory body, government or governmental
agency or body, domestic or foreign, having jurisdiction over such Investor or its properties, except for any conflict, breach,
violation or default which is not reasonably likely to have a material adverse effect on such Investor’s performance of
its obligations hereunder or the consummation of the transactions contemplated hereby.

 

(e)
The Investor is a party to a confidentiality agreement with the Company, pursuant to which it will maintain the confidentiality
of, and not use in any way (including not trading on the basis of) all information acquired in connection with the transactions
contemplated herein prior to the public disclosure of that information by the Company.

 

(f)
Neither the Investor nor any Person acting on behalf of, or pursuant to any understanding with or based upon any information
received from, the Investor has, directly or indirectly, engaged in any purchases or sales of the securities of the Company (including,
without limitation, any Short Sales involving the Company’s securities) since the time that the Investor first discussed
the transactions contemplated hereby with the Company. “Short Sales” include, without limitation, all “short
sales” as defined in Rule 200 promulgated under Regulation SHO under the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), whether or not against the box, and all types of direct and indirect stock pledges, forward
sale contracts, options, puts, calls, short sales, swaps, “put equivalent positions” (as defined in Rule 16a-1(h)
under the Exchange Act) and similar arrangements (including on a total return basis), and sales and other transactions through
non-U.S. broker dealers or foreign regulated brokers. The Investor covenants that neither it, nor any Person acting on behalf
of, or pursuant to any understanding with or based upon any information received from, will engage in any purchases or sales of
the securities of the Company (including Short Sales) prior to the time that the Company confirms to the Purchaser in writing
that all material nonpublic information has been publicly disclosed.

 

(g)
The Investor represents that, except as set forth below, (i) it has had no position, office or other material relationship
within the past three years with the Company or persons known to it to be affiliates of the Company, (ii) it is not a, and it
has no direct or indirect association with any, FINRA member or an Associated Person (as such term is defined under the FINRA
Membership and Registration Rules Section 1011) as of the date hereof, and (iii) neither it nor any group of investors (as identified
in a public filing made with the Commission) of which it is a member, acquired, or obtained the right to acquire, 20% or more
of the Common Stock (or securities convertible or exercisable for Common Stock) or the voting power of the Company on a post-transaction
basis. Exceptions:

 

Those
matters disclosed in regulatory filings by the Investor and its affiliates

(If
no exceptions, write “none.” If left blank, response will be deemed to be “none.”)

 

    	5

     

    

 

(h)
The Investor acknowledges that it has had the opportunity to review this Agreement (including all exhibits and schedules thereto)
and the SEC Reports and has been afforded (i) the opportunity to ask such questions as it has deemed necessary of representatives
of the Company and to receive answers from such representatives concerning the terms and conditions of the offering of the Shares
and the merits and risks of investing in the Shares; (ii) access to information about the Company and its financial condition,
results of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and
(iii) the opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable effort
or expense that is necessary to make an informed investment decision with respect to the investment.

 

9.
Except as expressly set forth in this Agreement to the contrary, each party shall pay the fees and expenses of its advisers,
counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation,
execution, delivery and performance of this Agreement.

 

10.
Notwithstanding any investigation made by any party to this Agreement, all covenants, agreements, representations and warranties
made by the Company and the Investor herein will survive the execution of this Agreement, the delivery to the Investor of the
Shares being purchased and the payment therefor.

 

11.
This Agreement may not be modified or amended except pursuant to an instrument in writing signed by the Company and the Investor.

 

12.
In case any provision contained in this Agreement should be invalid, illegal or unenforceable in any respect, the validity,
legality and enforceability of the remaining provisions contained herein will not in any way be affected or impaired thereby.

 

13.
This Agreement will be governed by, and construed in accordance with, the internal laws of the State of New York, without
giving effect to the principles of conflicts of law that would require the application of the laws of any other jurisdiction.

 

14.
This Agreement may be executed in counterparts, each of which will constitute an original, but all of which, when taken together,
will constitute but one instrument, and will become effective when counterparts have been signed by each party hereto and delivered
to the other party, and such counterparts may be delivered electronically.

 

15.
This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and
is not for the benefit of, nor may any provision hereof be enforced by, any other Person.

 

16.
The Investor acknowledges and agrees that such Investor’s receipt of the Company’s counterpart to this Agreement
shall constitute written confirmation of the Company’s sale of Shares to such Investor.

 

[SIGNATURE
PAGES FOLLOW]

 

    	6

     

    

 

INVESTOR
SIGNATURE PAGE

 

Number
of Shares: 1,460,280

 

Purchase
Price Per Share: $3.424

 

Aggregate
Purchase Price: $4,999,998.72

 

Please
confirm that the foregoing correctly sets forth the agreement between us by signing in the space provided below for that purpose.

 

Dated
as of January 20, 2021

 

INVESTOR

 

	By:
    	/s/
    Neal C. Bradsher 	 
	Print
    Name:	Neal
    C. Bradsher	 
	Title:
    	President
                                         of Broadwood Capital, Inc. (the General Partner of Broadwood Partners, L.P.)

Name
in which Securities are to be registered: Broadwood Partners, L.P.

Mailing
Address: c/o Broadwood Capital, Inc., 142 West 57th Street, 11th Floor, New York, NY 10019

 

Facsimile
Number: N/A

 

Email
Address:

 

Taxpayer
Identification Number:

 

Manner
of Settlement of the Shares: DWAC (The Shares will be sent from the Company’s transfer agent, American Stock Transfer &
Trust Company, by DWAC to your prime broker. You must contact your prime broker and ask them to initiate the DWAC
or you will not receive the Shares. The Shares will only be released after the Company’s receipt of the funds.)

 

	Name
    of DTC Participant (broker-dealer at which the account or accounts to be credited with the Shares are maintained)	 	Please
    see the attached instructions
	 	 	 
	DTC
    Participant Number	 	__________________________
	 	 	 
	Name
    of Account at DTC Participant being credited with the Shares	 	__________________________
	 	 	
	Account
                                         Number at DTC Participant being credited with the Shares
	 	__________________________

 

    	7

     

    

 

Agreed
and Accepted this 20th day of January, 2021:

 

	OncoCyte
    Corporation	 
	 	                  	 
	By:	/s/
    Mitch Levine 	 
	Name:	Mitch
    Levine	 
	Title:
    	CFO
    	 

 

Sales
of the Shares purchased hereunder were made pursuant to a registration statement or in a transaction in which a final prospectus
would have been required to have been delivered in the absence of Rule 172 promulgated under the Securities Act.

 

    	8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}]]